

Heterocyclic Chemistry

2-[(1*E*,3*E*)-4-Arylbuta-1,3-dien-1-yl]-4*H*-chromen-4-ones as Dienes in Diels–Alder Reactions – Experimental and Computational Studies

Hélio M. T. Albuquerque,^[a] Clementina M. M. Santos,^[a,b] Carlos F. R. A. C. Lima,^[a,c] Luís M. N. B. F. Santos,^[c] José A. S. Cavaleiro,^[a] and Artur M. S. Silva^{*[a]}

Abstract: The synthesis and reactivity of 2-[(1*E*,3*E*)-4-arylbuta-1,3-dien-1-yl]-4*H*-chromen-4-ones as dienes in Diels–Alder (DA) reactions with several electron-poor and electron-rich dienophiles under microwave irradiation was studied. The optimized reaction conditions were achieved with *N*-methylmaleimide as the dienophile and Sc(OTf)₃ (OTf = triflate) as a Lewis acid under microwave-assisted and solvent-free conditions. The Lewis acid improved the reaction yields as it prevented the adducts obtained from undergoing a second DA reaction; thus, the for-

mation of a bisadduct was avoided. The $\alpha,\beta,\gamma,\delta$ -diene of the starting chromones was the most reactive, and the computational results confirmed the experimental findings. Theoretical calculations also provided a rationale for the unexpected lack of reactivity shown by some dienophiles. The adducts prepared were dehydrogenated with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ); however, the aza adducts were sensitive to the highly energetic reaction conditions necessary for the aromatization.

Introduction

Chromones (or 4*H*-chromen-4-ones) constitute a well-known class of naturally occurring oxygen-containing heterocycles. These compounds exhibit important biological properties such as anticancer,^[1] cytotoxic,^[2] antioxidant,^[1b,3] anti-inflammatory,^[4] and antifungal^[5] activities. Their reactivities in several chemical transformations, namely, oxidations, thiations, hydrogenations, photolysis, condensations, dimerizations, and Diels–Alder (DA) reactions have been reported widely.^[6] Since its discovery in 1928, the DA reaction, including its hetero variant, has remained an active research field and is the key step in the synthesis of a large variety of organic compounds.^[7]

The use of chromone derivatives as dienes was first reported in 1954 and involved the DA reaction of 2-styrylchromones with maleic anhydride,^[8] and later with *N*-arylmaleimides^[9] to afford the corresponding 1,2,3,9a-tetrahydroxanthone adducts. However, in 1992, Letcher and Yue revised the structure of the obtained adducts to the isomeric 1,2,3,4-tetrahydroxanthenes on the basis of extensive NMR and IR spectroscopy studies.^[10] Years later, Kelkar et al. reported the use of 2-vinylchromones in [4+2] cycloaddition reactions with electron-rich enamine di-

enophiles to provide several xanthone-type compounds.^[11] Recently, the reactivity of (*E*)-2-(4-arylbut-1-en-3-yn-1-yl)chromones in DA reactions with *N*-methylmaleimide (NMM) as the dienophile was used for the synthesis of xanthone-1,2,3-triazole dyads.^[12] The diene system of (*E*)-2-(4-arylbut-1-en-3-yn-1-yl)chromones was unreactive under classical heating conditions; however, the DA reaction under microwave (MW) irradiation afforded the expected 1,2,3,4-tetrahydroxanthone structure, which was further transformed to the aforementioned dyads. Meanwhile, our research group also tested the reactivity of 3-styrylchromones as dienes in [4+2] cycloaddition reactions with electron-poor dienophiles. Once again, the respective adducts were obtained in better yields through a MV-assisted protocol than through classical heating conditions. Owing to the advantages provided by the use of MV irradiation in DA reactions, experimental and computational studies on the MV-assisted DA reactions of 2-[(1*E*,3*E*)-4-arylbuta-1,3-dien-1-yl]-4*H*-chromen-4-ones with several electron-poor and electron-rich dienophiles are disclosed herein. On the basis of the reactivity of each diene system of the starting chromones, we expected to synthesize styryl-substituted xanthenes (through the DA reaction of the 3,2: α,β -diene) or aryl-substituted flavones (through the DA reaction of the $\alpha,\beta,\gamma,\delta$ -diene), but the results indicate that only flavone-type compounds are formed (Figure 1).

Xanthone and flavone derivatives both have unquestionable biological benefits, as supported by several reports of their use as anticancer, antioxidant, and anti-inflammatory agents, among others.^[13] Although the activities of simple xanthone^[14] or flavone^[15] scaffolds addresses only one biological target, there is a general belief that agents that modulate more than one target could have improved efficiencies compared with

[a] Department of Chemistry & QOPNA, University of Aveiro, Campus de Santiago, 3810-193 Aveiro, Portugal
E-mail: artur.silva@ua.pt
<https://sites.google.com/site/artursilva/ua/silva-ams>

[b] School of Agriculture, Polytechnic Institute of Bragança, Campus de Santa Apolónia, 5300-253 Bragança, Portugal

[c] CIQ-UP, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Porto, Portugal

Supporting information and ORCID(s) from the author(s) for this article are available on the WWW under <http://dx.doi.org/10.1002/ejoc.201601072>.




Figure 1. Two possible sites for DA reactions in 2-[(1*E*,3*E*)-4-arylbuta-1,3-dien-1-yl]-4*H*-chromen-4-ones. R, R' = electron-withdrawing group (EWG) or electron-donating group (EDG).

those of single-target drugs for complex multifactorial diseases such as cancer or Alzheimer's disease.^[16] In the present work, *N*-methyl- and *N*-phenylmaleimides were used as dienophiles to provide dyads bearing the isoindoline-1,3-dione unit, which is an interesting scaffold that has already been studied in a multitarget approach for the treatment of cancer^[17] and Alzheimer's disease.^[18] Thus, it is expected that the new hybrid structures may have greater biological relevance in the multitarget-drug research field than the simpler xanthone and flavone derivatives.


Results and Discussion

DA Reactions of 2-[(1*E*,3*E*)-4-Arylbuta-1,3-dien-1-yl]-4*H*-chromen-4-ones

2-[(1*E*,3*E*)-4-Arylbuta-1,3-dien-1-yl]-4*H*-chromen-4-ones (**3a–3e**) were prepared in good yields (68–80 %) through the base-catalyzed aldol condensation of 2-methyl-4*H*-chromen-4-one (**1**) with the appropriate cinnamaldehyde **2a–2e** according to a previously reported methodology (Scheme 1).^[19] 2-Methyl-4*H*-chromen-4-one was prepared through a previously reported three-step Baker–Venkataraman sequence in good overall yield,^[14c] whereas the cinnamaldehydes **2b–2d**, which are not commercially available, were obtained through palladium-catalyzed cross-coupling reactions of aryl iodides with acrolein diethyl acetal.^[20]

On the basis of our previous results on the MV-assisted DA reactions of 2-[(1*E*)-4-arylbut-1-en-3-yn-1-yl]chromones,^[12] we initially attempted the DA reaction of chromone **3c** with in-

creasing amounts of NMM in dry *N,N*-dimethylformamide (DMF) for 40 min at 160 °C under multimode MV irradiation (Table 1, Entries 1–3). Adduct **5c** (NMR data in Supporting Information) was isolated as the major product in 30–31 % yield (Table 1, Entries 1–3). The DA reaction occurred at the $\alpha,\beta,\gamma,\delta$ -diene, and the structure of adduct **5c** arises from the olefin migration of the expected DA cycloadduct **4c**, which was also isolated (Table 1, Entry 10). The bisadduct **7c** was isolated as a mixture of four diastereomers (two major diastereomers and traces of the other two) when a large excess of NMM was employed (Table 1, Entries 6–9). Its formation should involve a cascade of four reactions: the DA reaction at the $\alpha,\beta,\gamma,\delta$ -diene gives intermediate **4c** and subsequent olefin migration affords adduct **5c**, the diene of which undergoes a new DA reaction to yield an intermediate structure that provides bisadduct **7c** upon olefin migration (Scheme 2). The formation of bisadduct **7c** was further confirmed by the reaction of the isolated adduct **5c** with NMM under in solvent-free conditions with monomode MV irradiation (Table 3). The two major diastereomers found in a 52:48 % mixture were assigned as structures I and II (Scheme 3), and we were able to isolate the former one in a pure form and fully characterize it (NMR data in Supporting Information). The stereochemistry of diastereomer I of bisadduct **7c** was assessed through the observed NOE cross-peaks of (1) H-14c with H-14b and H-3a; (2) H-4 with H-3a and H-5, which indicate the formation of the *endo* product from the first DA reaction; and (3) H-5b with H-5a and H-8a as well as the absence of close proximity between H-5a with H-14b, which suggests that the second DA reaction also afforded an *endo* adduct. However, the second addition can occur at the same face as the first one to yield the *endo/endo(cis)* adduct or at the opposite face to afford the *endo/endo(trans)* adduct (Scheme 3). Then, each one of these




Scheme 1. Synthesis of chromones **3a–3e** used as dienes in DA reactions.

diastereomers undergoes olefin migration to provide two diastereomers. In the NOESY spectrum of a mixture enriched in diastereomer II of bisadduct **7c**, one can deduce the close proximity of H-5a with H-5b and H-14b as well as H-5b with H-8a, which confirms the *endo/endo(cis)* diastereomer (Scheme 3). In the spectrum of the crude reaction mixture, we observed the typical signals of the diastereomers I and II as well as other small ones corresponding to the H-8a, OMe, and *N*-Me signals of another two compounds, which were assigned to diastereomers III and IV (trace amounts). The variation of the tempera-


ture, reaction time, or dienophile amount did not improve the yields of adduct **5c** or bisadduct **7c** (Table 1, Entries 4–10). Interestingly, if the reaction was performed for 10 min, adduct **6c** (NMR data in Supporting Information) was isolated in 6 % yield (Table 1, Entry 5). In this case, the DA reaction occurred at the 3,2:α,β-diene to give a styryl-substituted tetrahydroxanthene structure. By performing the reaction at 130 °C, it was possible to isolate derivative **4c** in 8 % yield (Table 1, Entry 10). This confirms that the more stable adduct **5c** results from the olefin migration of the expected DA cycloadduct **4c** (NMR data in

Table 1. Optimization of the DA reaction of chromone **3c** with NMM under multimode MW irradiation. The reactions were performed in dry DMF (10 μL).




Entry	NMM [equiv.]	T [°C]	Time [min]	5c Yield [%] ^[a]	7c Yield [%] ^[b]	3c Recovered [%] ^[a]	Entry	NMM [equiv.]	T [°C]	Time [min]	5c Yield [%] ^[a]	7c Yield [%] ^[b]	3c Recovered [%] ^[a]
1	1	160	40	31	–	10	6	10	160	10	48	28	–
2	3	160	40	30	–	–	7	15	160	20	21	31	–
3	5	160	40	30	7	–	8	10	160	40	21	21	–
4	5	160	20	35	25	–	9	10	100	20	25	17	Traces
5 ^[c]	5	160	10	22	Traces	Traces	10 ^[d]	10	130	10	30	Traces	Traces

[a] Isolated yields. [b] Isolated yield of a mixture of diastereomers. [c] Derivative **6c** isolated in 6 % yield. [d] Derivative **4c** isolated in 8 % yield.



Scheme 2. Tandem DA/olefin migration processes to form bisadduct **7c**.



Scheme 3. Stereochemistry (NOESY) of the olefin migration of **7c** *endo/endo(trans)* and *endo/endo(cis)* products.

Supporting Information). Our aforementioned preliminary experimental results strongly suggest that the $\alpha,\beta,\gamma,\delta$ -diene system is the most reactive or at least affords the more thermodynamically stable DA product. To obtain more insights into this DA reaction, we evaluated its thermodynamic feasibility by computational methods at the M06-2X/6-31+G(d,p) level of theory (detailed results are presented in Table S1). We started with the conformational analysis of the reactants **3a**, **3c**, **3d**, and **3e**, as only the *cis* double bonds are reactive towards the DA reaction.

The results indicate that the all-*trans* reactant is the major species with a molar fraction of around 0.89 at $T = 160\text{ }^\circ\text{C}$ (the temperature at which most reactions were performed). The species with all *cis* double bonds has a molar fraction of less than 0.01 and can in principle be ignored. The two reactive conformers *cis*-3,2: α,β -diene (which yields **6** upon DA reaction) and *cis*- $\alpha,\beta,\gamma,\delta$ -diene (which yields **4**) are present in small amounts of ca. 0.08 and 0.02, respectively. However, as the conversion between these isomers is rather fast at high temperatures, these quantities should suffice for the respective DA reactions to proceed smoothly.^[21] The influence of the substituent R group (Figure 1) in the conformational distribution was found to be negligible. The calculated energy levels of the highest occupied molecular orbital and the lowest unoccupied molecular orbital (HOMO/LUMO) confirm the kinetic viability of the direct DA reaction through comparison with the calculated HOMO and LUMO of the NMM dienophile (Table S4, Supporting Information) and also vary very little with the substituent R.

These results suggest that the influence of the R group on the intrinsic thermodynamic and kinetic DA reactivity of **3** is of minor importance, as is consistent with the rather large distance of the substituent from the reactive diene centers. Hence, to speed up the calculations, only **3a** (R = H) was considered for the subsequent computational studies. We also evaluated each possible reaction of **3a** with NMM separately to yield the four possible products (**4a**, **5a**, **6a**, and **7a**) presented in Table 1.

As **4a**, **5a**, and **6a** are isomers, the direct comparison between their energies gives information about which reaction pathway is thermodynamically preferred (Table S2, Supporting Information). The optimized structures of **4a**, **5a**, **6a**, and **7a** are presented in Table S5 (Supporting Information); various possible stable conformations were found for these compounds, but only the minimum energy configurations were considered. The energetic analysis indicates that the stabilities of **5a** and **6a** are very similar, $\Delta H_{298\text{K}}(\mathbf{5a} \rightarrow \mathbf{6a}) \approx 0\text{ kJ mol}^{-1}$ ($H_{298\text{K}}$ is the calculated enthalpy at $T = 298.15\text{ K}$). However, the energy difference between their precursors, **4a** and **6a**_i, respectively, which are formed through the initial DA reaction and before the olefin migration, is much more substantial, $\Delta H_{298\text{K}}(\mathbf{4a} \rightarrow \mathbf{6a}_i) \approx 29\text{ kJ mol}^{-1}$. The $\Delta H_{298\text{K}}$ values for the olefin migrations were calculated as -27 kJ mol^{-1} for **4a** \rightarrow **5a** and -57 kJ mol^{-1} for **6a**_i \rightarrow **6a**. The computational results also indicate that the DA reactions with NMM (**3** \rightarrow **4**, **3** \rightarrow **6**, **5** \rightarrow **7**) are significantly favored energetically, and the calculated $\Delta H_{298\text{K}}$ values are in the order of -120 to -150 kJ mol^{-1} . To better visualize these results, the calculated relative enthalpy ($T = 298.15\text{ K}$) versus reaction coordinate diagram is shown in Figure 2 for the DA reaction of **3a** with NMM (to yield the two intermediates **4a** and **6a**_i) and subsequent olefin migration (to form **5a** and **6a**, respectively).

These results support the experimental findings by indicating that (1) **6** should be a minor product of the DA reaction, (2) the preferred pathway for product **7** should be a second DA reaction of **5**, and (3) the olefin migration of the DA adducts should be thermodynamically spontaneous.

To improve the yields of adducts **5**, the reaction was performed under solvent-free conditions with monomode MV irradiation. Thus, the DA reaction of chromone **3c** with NMM was performed with the variation of the amount of dienophile and the reaction time (Table 2, Entries 1–5). The best yield for adduct **5c** (47 %) was obtained in 10 min with 2 equiv. of NMM, and 5 % of the starting chromone **3c** was recovered (Table 2, Entry 3). The reactions at 130 and 100 $^\circ\text{C}$ with 2 equiv. of NMM





Figure 2. Enthalpy (at $T = 298.15$ K) versus reaction coordinate diagram for the DA reaction of **3a** with NMM, calculated at the M06-2X/6-31+G(d,p) level of theory.

for 15 min (Table 2, Entries 6 and 7) afforded less byproduct, and the yield of adduct **5c** was higher at 130 °C, at which 37 % of the starting chromone **3c** was recovered. Owing to the moderate yields of adduct **5c**, the influence of the Lewis acid was assessed. If a stoichiometric amount of AlCl_3 was employed at different temperatures, adduct **5c** was obtained in low yields (27–29 %), and 45–57 % of the starting chromone **3c** was recovered (Table 2, Entries 8 and 9). If the Lewis acid was changed to $\text{Sc}(\text{OTf})_3$ (OTf = triflate) and the amount of dienophile was

varied, the yield of adduct **5c** increased to 62–67 %, and the best yield was achieved with 3 or 4 equiv. of NMM (Table 2, Entries 10–12). A single reaction was attempted with 30 mol-% of $\text{Sc}(\text{OTf})_3$ for 10 min at 165 °C (Table 2, Entry 13), but, unfortunately, the yield of adduct **5c** decreased to 37 %; this result implies that the effect of $\text{Sc}(\text{OTf})_3$ is stoichiometric rather than catalytic. In our particular case, the Lewis acid can complex with the carbonyl groups of NMM or with the carbonyl group of chromone **3c**. The chelation with NMM makes this dienophile more electron-poor and, as a consequence, the DA reaction is favored with an electron-rich diene. Furthermore, the chelation of the Lewis acid with the carbonyl group of chromone **3c** makes the 3,2: α,β -diene more electron-poor, and the DA reaction at this site is disfavored (Figure 3A). The chelation with the carbonyl group of adduct **5c** also makes the newly formed diene more electron-poor; once again, the DA reaction is disfavored and, consequently, the yield of bisadduct **7c** decreases (Figure 3B).

To reinforce this idea, DA reactions of adduct **5c** with an excess of NMM in the presence or absence of $\text{Sc}(\text{OTf})_3$ were performed (Table 3, Entries 1–3). Both DA reactions performed in the absence of $\text{Sc}(\text{OTf})_3$ afforded bisadduct **7c** as a mixture of diastereomers in 48 and 60 % yield with 20–37 % of the starting adduct **5c** recovered (Table 3, Entries 1 and 2). For the reaction in the presence of a stoichiometric amount of $\text{Sc}(\text{OTf})_3$, bisad-

Table 2. The optimization of the DA reaction of chromones **3a–3e** with NMM under solvent-free conditions with monomode MW irradiation.



Entry	Derivative	NMM [equiv.]	T [°C]	Time [min]	Lewis acid	5 Yield [%] ^[a]	3 Recovered [%] ^[a]
1	3c	1	165	15	–	37	33
2	3c	2	165	15	–	44	–
3	3c	2	165	10	–	47	5
4	3c	2	165	5	–	45	26
5 ^[b]	3c	5	165	15	–	25	–
6	3c	2	130	15	–	40	37
7	3c	2	100	15	–	20	66
8 ^[c]	3c	2	165	10	AlCl_3	29	45
9 ^[c]	3c	2	130	15	AlCl_3	27	57
10 ^[c]	3c	2	165	10	$\text{Sc}(\text{OTf})_3$	62	21
11 ^[c]	3c	3	165	10	$\text{Sc}(\text{OTf})_3$	67	5
12 ^[c]	3c	4	165	10	$\text{Sc}(\text{OTf})_3$	67	8
13 ^[d]	3c	3	165	10	$\text{Sc}(\text{OTf})_3$	37	–
14 ^[c]	3c	2	165	15	$\text{Sc}(\text{OTf})_3$	59	26
15 ^[c]	3c	2	130	15	$\text{Sc}(\text{OTf})_3$	47	17
16 ^[c]	3a	3	165	10	$\text{Sc}(\text{OTf})_3$	77	–
17 ^[c]	3b	3	165	10	$\text{Sc}(\text{OTf})_3$	55	14
18 ^[c]	3d	3	165	10	$\text{Sc}(\text{OTf})_3$	71	–
19 ^[c]	3e	3	165	10	$\text{Sc}(\text{OTf})_3$	52	25

[a] Isolated yield. [b] 25 % of bisadduct **7c** was isolated. [c] 100 mol-% of Lewis acid. [d] 30 mol-% of Lewis acid.





Figure 3. Effect of Lewis acid on the DA reaction: (A) chelation with chromone **3c** and NMM, (B) chelation with adduct **5c** and *N*-methylmaleimide.

duct **7c** was obtained as a mixture of diastereomers in only 15 % yield, and 75 % of **5c** was recovered (Table 3, Entry 3). These results confirm our suspicions that the Lewis acid chelation makes the 3,2:α,β-diene more electron-poor and directs the DA reaction towards **5c**.

Table 3. DA reaction of **5c** with NMM in the presence or absence of Sc(OTf)₃. Reactions performed with 6 equiv. of NMM.



Entry	Time [min]	Lewis acid	7c Yield [%] ^[a]	5c Recovered [%] ^[b]
1	20	–	48	37
2	30	–	60	20
3 ^[c]	20	Sc(OTf) ₃	15	75

[a] Isolated yield of a mixture of diastereomers. [b] Isolated yield. [c] 100 mol-% of Lewis acid.

The best reaction conditions for adduct **5c** were achieved with 3 equiv. of NMM in the presence of 1 equiv. of Sc(OTf)₃ for 10 min at 165 °C (Table 2, Entry 11). The same conditions were applied to chromones **3a**, **3b**, **3d**, and **3e** (Table 2, Entries 16–19), and the corresponding adducts **5a**, **5b**, **5d**, and **5e** were obtained in moderate-to-good yields (52–77 %). To confirm our previous suggestion for the formation of the *endo* adduct **5**, a NOESY experiment was performed on adduct **5e** to address the stereochemistry of the reaction. The NOE cross-peaks showed the close proximity of H-3a with H-4 and H-7a; therefore, the adducts **5** are *endo* products (Figure 4).

The effect of Lewis acid chelation was further evaluated by computational chemistry at the M06-2X/6-31+G(d,p) level of theory (the detailed results are presented in the Supporting Information). The results indicate that Sc(OTf)₃ will bind preferentially to the C=O group of the chromone ring, and chelation with other groups or atoms of the diene or the dienophile is of minor importance. Chelation with a Lewis acid seems not to alter significantly the shapes of the HOMOs and LUMOs of **3a** and **5a**. However, the computational results suggest that chela-

















Figure 4. Most important NOE cross-peaks of adduct **5e**.

tion reduces the overall reactivity of the dienes towards the DA reaction because it (1) increases the HOMO/LUMO gap between the diene and dienophile (by decreasing the HOMO energy of the diene) and (2) decreases the double-bond character of the reactive chromone double bond and, thus, decreases the reactivity of the 3,2:α,β-diene. Hence, on the basis of the experimental and computational findings, the most probable cause for the increased yield of product **5** in the presence of Sc(OTf)₃ is that chelation reduces the reactivity of **5** towards the second DA reaction, which consumes it to afford bisadduct **7**.

With these results in hand, we turned our attention to the scope of dienophiles in DA reactions with chromone **3c**, as depicted in Table 4. *N*-Phenylmaleimide afforded adduct **8** in 66 % yield (Table 4, Entry 1). The reactivities of dimethyl and diethyl acetylenedicarboxylate with chromone **3c** were also tested, and the expected aromatic products **9a** and **9b** (NMR data in Supporting Information) were obtained in 30–45 % yield (Table 4, Entries 2–4).

The dienophile scope was further extended to diethyl and diisopropyl azodicarboxylate (DEAD and DIAD, respectively; Table 4, Entries 5 and 6) to afford the expected adducts **10a** and **10b** in 22 and 57 % yield, respectively. In the reaction with DEAD, derivative **11** was isolated in 22 % yield as the product of an Alder-ene reaction of adduct **10a**. The formation of this Alder-ene product **11** (NMR data in Supporting Information) can be explained on the basis of a tandem DA/Alder-ene process (Scheme 4). To avoid the formation of the Alder-ene product **11**, the reaction was attempted at 80 and 100 °C; however, no reaction products were observed. By performing the reaction at 130 °C, cycloadduct **10a** was isolated in trace amounts together with unreacted chromone **3c** and derivative **11** in 30 % yield. 4-Phenyl-1,2,4-triazoline-3,5-dione (PTAD) was expected to show similar or even improved reactivity compared with those of maleimides or azodicarboxylates. Unfortunately, no DA products were observed when the reaction was performed at different temperatures and in the presence or absence of DMF as solvent (Table 4, Entries 7–9). The reason for this may be that the high temperatures employed in DA reactions probably lead to the dimerization of PTAD,^[22] and this reaction competes with the DA reaction. Electron-poor dienophiles such as diethyl fumarate and maleate were extremely reluctant towards the DA reaction with chromone **3c**. Even at higher temperatures and longer reaction times, no DA reaction was observed. Instead, more degradation products and less recovered chromone were detected (Table 4, Entries 10–13). Reactions involving the electron-rich dienophile 3,4-dihydro-2*H*-pyran (Table 4, Entries 14 and 15) were attempted at different temperatures, but no DA reaction occurred.


Table 4. Dienophile scope in the DA reactions of chromone **3c** under monomode MW irradiation; the reactions were performed under solvent-free or neat conditions.

Entry	Dienophile	T [°C]	Time [min]	Product	Yield [%] ^[a]	3c Recovered [%] ^[a]
1 ^[b]		165	10		66	–
2		130	15		30	33
3		165	15		35	–
4		165	15		45	–
5 ^[e]						
6		165	10		57	–
7		165	10	[^d]	–	63
8 ^[c]		130	10	[^d]	–	40
9 ^[c]		165	10	[^d]	–	–
10		130	10	no reaction	–	90
11		165	10	no reaction	–	90
12		165	40	[^d]	–	60
13		200	40	[^d]	–	50
14		100	15	no reaction	–	90
15		165	15	no reaction	–	90

[a] Isolated yield. [b] Addition of 100 mol-% of Sc(OTf)₃. [c] DMF (0.1 mL) as solvent. [d] Unidentified byproducts. [e] The reaction with DEAD afforded the expected DA cycloadduct and the other product from the tandem DA/Alder-ene process.

In general, the relative reactivity of the dienophiles is indicated accurately by the calculated HOMO(diene)/LUMO(dienophile) energy differences, and there is some tendency for higher yields to be observed for lower HOMO/LUMO energy gaps. For instance, the highest HOMO/LUMO gap was observed for the dienophile in Table 4, Entries 14 and 15, the low reactivity of which may explain why no DA reaction occurred. The HOMO/LUMO energies were calculated at the M06-2X/6-31+G(d,p) and MP2/6-31+G(d,p) levels of theory. The detailed results are presented in Table S4 (Supporting Information), and both methods predict similar tendencies in the HOMO/LUMO energies. How-

ever, there are some cases that deviate from this analysis. In Table 4, Entries 7–9 and 12–13, although the calculated HOMO/LUMO gaps are slightly higher than those for the most reactive dienophiles, the absence of DA reaction may mostly be due to the extensive decomposition of the dienophile in the reaction medium. For Table 4, Entries 10 and 11, the failure of the DA reaction is harder to explain; the HOMO/LUMO gap is comparable to those of the most reactive dienophiles, no unidentified byproducts were detected, and most of the unreacted reagent was recovered. Therefore, we turned our attention to the corresponding DA product analogous to **5**.




Scheme 4. Tandem DA/Alder-ene process to form **11**.

The optimized geometry of this product (presented in Table S5, Supporting Information) evidences the existence of significant steric repulsion between the ester groups and the chromone and phenyl rings. This increases the calculated $\Delta_r H_{298K}$ for the DA reaction between **3a** and diethyl fumarate to yield the product analogous to **5a** by ca. 10 and 40 kJ mol⁻¹ relative to the reaction **3a** + NMM \rightarrow **5a** and the analogous reactions involving the similar dienophiles used in Table 4, Entries 5 and 6, respectively (Table S3, Supporting Information). In these last cases, the geometries of the N atoms in the DA products avoids significant steric repulsions, and the reactions are more favored. This computational analysis suggests that the DA reaction between **3** and the dienophiles in Table 4, Entries 10–13, to yield the products analogous to **4** and **5** is thermodynamically or kinetically less favored owing to significant intramolecular steric repulsion.

Aromatization of DA Adducts

Once adducts **5a–5e** were obtained, we thought it would be interesting to further aromatize them to flavone derivatives. Several methodologies using 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) have been reported;^[23] nevertheless, our initial choice was a successful method that we employed previously for similar oxidations.^[12] Therefore, adduct **5c** was heated in toluene at 100 °C with 3 equiv. of DDQ (Table 5, Entry 1). After 4 h, the starting adduct **5c** was consumed, and the oxidized product **12c** was obtained in 34 % yield, together with the semioxidized product **13c** (NMR data in Supporting Information) in 60 % yield (Table 5, Entry 1). With a more polar solvent, 1,4-dioxane, and an increased amount of DDQ (Table 5, Entry 2), only the semioxidized derivative **13c** was obtained in 52 % yield. With 1,4-dioxane, and an increased amount of DDQ (Table 5, Entry 2), only the semioxidized derivative **13c** was obtained in 52 % yield. With 1,2,4-trichlorobenzene (1,2,4-TCB) as the solvent (Table 5, Entry 3), the semioxidized derivative **13c** was isolated in 15 %; however the oxidized derivative **12c** was obtained in only 38 % yield. The low yields of derivative **12c** can be explained on the basis of the stability given by the presence of a conjugate diene in the semioxidized derivative **13c**. Furthermore, the relatively long reaction times may contribute to the degradation of either the starting adduct or the oxidized products. MV-assisted reaction conditions were employed for the oxidation of adduct **5c** in 1,2,4-TCB at 165 °C for 25 min (Table 5, Entry 4); the desired oxidized derivative **12c** was obtained in 90 % yield, and no semioxidized product **13c** was detected. These reaction conditions were also applied to adducts **5a**, **5b**, **5d**, and **5e** to afford the oxidized products **12a**, **12b**, **12d**, and **12e** (NMR data in Supporting Information) in high yields (Table 5, Entries 5–8). At this stage, derivatives **12a–12e** were obtained in two steps; the intermediate DA adducts **5a–5e** were isolated in the first step and further oxidized with DDQ. To address if the oxidation of adducts **5** without purification was advantageous, chromone **3c** was reacted with NMM in the presence of Sc(OTf)₃, and the formed adduct was oxidized with

Table 5. Aromatization of adducts **5a–5e**.




Entry	Adduct	DDQ [equiv.]	Heating method	Solvent	T [°C]	Time	12 Yield [%] ^[a]	13c Yield [%] ^[a]
1	5c	3	oil bath	toluene	100	4 h	34	60
2	5c	5	oil bath	1,4-dioxane	100	4 h	–	52
3	5c	3	oil bath	1,2,4-TCB	190	24 h	38	15
4	5c	4	MW ^[b]	1,2,4-TCB	165	25 min	90	–
5	5a	4	MW ^[b]	1,2,4-TCB	165	25 min	85	–
6	5b	4	MW ^[b]	1,2,4-TCB	165	25 min	75	–
7	5d	4	MW ^[b]	1,2,4-TCB	165	25 min	80	–
8	5e	4	MW ^[b]	1,2,4-TCB	165	25 min	70	–

[a] Isolated yield. [b] Monomode MW irradiation.

DDQ in 1,2,4-TCB at 165 °C for 25 min in a one-pot process. The oxidized product **12c** was obtained in 16 % yield along with adduct **5c** in 28 % yield. The low yield of **12c** can be explained by the chelation of the Lewis acid with the carbonyl group of adduct **5c**; the chelation makes the cyclohexene ring electron-poor by conjugation, and the hydride abstraction by DDQ is disfavored. The same experiment was performed under the same reaction conditions but in absence of the Lewis acid. Unfortunately, the reaction afforded the oxidized product **12c** only in 20 % yield, and no adduct **5c** was isolated. In the absence of Lewis acid, the DA reaction affords more byproducts, including the bisadduct **7c**, and this may be the reason that the yield of the oxidized product **12c** is not improved in the absence of Sc(OTf)₃. To sum up, the one-pot DA/oxidation processes was an inefficient and disadvantageous methodology compared to the two-step procedure.


Adduct **8** was also oxidized under the best reaction conditions for adducts **5a–5e** to afford derivative **14** in 86 % yield (Scheme 5).



Scheme 5. Aromatization of adduct **8**.

The oxidations of cycloadducts **10a** and **10b** were not straightforward, because C–N bonds break readily upon oxidation. Therefore, the initial oxidation conditions employed to cycloadduct **10a** were less harsh, and DDQ was used in 1,4-dioxane at 100 °C for 24 h. Unfortunately, no oxidized product was detected, and 72 % of the starting cycloadduct **10a** was recovered. Therefore, highly energetic conditions were employed with DDQ in 1,2,4-TCB at 165 °C under MV irradiation for 25 min. Several unidentified byproducts were observed, and no oxidized product was detected.

Despite the unsuccessful attempts to oxidize cycloadduct **10a**, the aromatization of cycloadduct **10b** was also attempted under MV irradiation (Scheme 6). The oxidation process occurred but was inefficient, as the oxidized product **15b** was isolated in only 17 % yield. In the ¹H NMR spectrum of derivative **15b**, two broad singlets at $\delta = 6.07$ and 7.88 ppm, assigned to 1-NH and 4-NH, respectively, indicated that the N–N single bond of the cycloadduct **10b** was broken during the oxidation reaction.



Scheme 6. Aromatization of cycloadduct **10b**.

Conclusions

The $\alpha,\beta,\gamma,\delta$ -diene system of chromones **3** were the most reactive in DA reactions with NMM as the dienophile to afford compounds **5**, which form through a DA reaction followed by an olefin migration. These results were confirmed by computational studies, which indicated that derivative **6** (DA reaction at the 3,2: α,β -diene, followed by an olefin migration) should be a minor product of DA reaction and that adducts **5** are thermodynamically more stable. However, for the DA reaction in DMF with an excess of NMM, the yields of adducts **5** were lower, and several byproducts were detected. The most relevant one resulted from a tandem DA/olefin migration/DA/olefin migration process to afford bisadduct **7** as a mixture of diastereomers. The formation of this byproduct was prevented by using Sc(OTf)₃ under solvent-free conditions, and, consequently, adducts **5** were obtained in higher yields. An investigation of the scope of dienophiles allowed us to conclude that electron-poor dienophiles are most reactive and that no DA reaction occurred for electron-rich dienophiles. The adducts obtained with maleimides were aromatized in high yields with DDQ under MV irradiation. However, the aromatization was not straightforward for aza adducts owing to the sensitive N–N single bonds, which were broken readily. The combination of the experimental and computational findings also indicates that the main features of the DA reactions studied are described accurately by the thermodynamic stabilities of the reaction products and intermediates and the HOMO/LUMO evaluation of the dienes and dienophiles within the frontier molecular orbitals (FMO) approach.

Experimental Section

General: The melting points were measured with a Büchi B-540 melting-point apparatus. The NMR spectra were recorded with a Bruker Avance 300 spectrometer (300.13 MHz for ¹H and 75.47 MHz for ¹³C) or Bruker Avance 500 spectrometer (500.13 MHz for ¹H and 125.77 MHz for ¹³C). Chemical shifts (δ) are reported in ppm, and coupling constants (*J*) are in Hz; the internal standard was tetramethylsilane (TMS). Unequivocal ¹³C NMR assignments were made with the aid of 2D gradient heteronuclear single quantum coherence (gHSQC) and gradient HMBC (gHMBC; delays for one-bond long-range C–H couplings were optimized for 145 and 7 Hz, respectively) experiments. Positive-ion ESI mass spectra were acquired with a QTOF 2 instrument. The sample (1 μ L) in chloroform solution (ca. 10^{−5} M) was diluted in 0.1 % trifluoroacetic acid/methanol solution (200 μ L). Nitrogen was used as nebulizer gas, and argon was used as the collision gas. The needle voltage was set to 3000 V, the ion source was set to 80 °C, and the desolvation temperature was 150 °C. The cone voltage was 35 V. Other low- and high-resolution mass spectra (EI, 70 eV) were measured with VG Autospec Q and M spectrometers. Elemental analyses were obtained with a LECO 932 CHNS analyzer. Preparative TLC was performed with Merck silica gel (60 DGF254). Column chromatography was performed with Merck silica gel (60, 70–230 mesh). All chemicals and solvents used were obtained from commercial sources and used as received or dried by standard procedures.

General Procedure for the Synthesis of 2-[(1*E*,3*E*)-4-Arylbuta-1,3-dien-1-yl]-4*H*-chromen-4-ones **3a–3e:** Sodium (0.11 g, 4.8 mmol) was added gradually to dry ethanol (5 mL), and the mix-

ture was stirred until it reached room temperature. 2-Methylchromone (**1**, 0.2 g, 1.2 mmol) and the appropriate cinnamaldehyde **2a–2e** (1.5 mmol) were added, and the reaction mixture was allowed to stand at room temperature until the 2-methylchromone disappeared completely. The solution was then poured into ice and water, and the pH was adjusted to 4 with dilute HCl. The solid was removed by filtration, dissolved in dichloromethane, and purified by silica gel column chromatography with dichloromethane as the eluent. The solvent was evaporated, and the residue was recrystallized from ethanol to give the 2-[(1*E*,3*E*)-4-arylbuta-1,3-dien-1-yl]-4*H*-chromen-4-ones **3a–3e**.

2-[(1*E*,3*E*)-4-Phenylbuta-1,3-dien-1-yl]-4*H*-chromen-4-one (3a**):** Yield 263 mg (80 %), orange solid, m.p. 144–146 °C (from EtOH). ¹H NMR (300 MHz, CDCl₃): δ = 6.27 (s, 1 H, 3-H), 6.38 (d, *J* = 15.3 Hz, 1 H, H-α), 6.91–7.03 (m, 2 H, H-γ, H-δ), 7.31–7.45 (m, 6-H, H-β, 3',4',5'-H), 7.48–7.51 (m, 1 H, 8-H), 7.52 (d, *J* = 8.5 Hz, 2 H, 2',6'-H), 7.68 (ddd, *J* = 8.6, 7.1, 1.7 Hz, 1 H, 7-H), 8.19 (dd, *J* = 7.9, 1.7 Hz, 1 H, 5-H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 110.3 (C-3), 117.8 (C-8), 123.6 (C-α), 124.1 (C-4a), 125.0 (C-6), 125.7 (C-5), 127.1 (C-2',6'), 128.9 (C-3',5'), 129.0 (C-4'), 133.7 (C-7), 136.3 (C-1'), 137.4 (C-β), 139.1 (C-δ), 156.0 (C-8a), 161.8 (C-2), 178.4 (C-4) ppm. EI-MS: *m/z* (%) = 274 (35) [M]⁺, 273 (100) [M – H]⁺, 257 (26), 221 (24), 197 (48). EI-HRMS: calcd. for C₁₉H₁₄O₂ [M]⁺ 274.0994; found 274.0999.

2-[(1*E*,3*E*)-4-(4-Chlorophenyl)buta-1,3-dien-1-yl]-4*H*-chromen-4-one (3b**):** Yield 259 mg (70 %), yellow solid, m.p. 180–182 °C (from EtOH). ¹H NMR (300 MHz, CDCl₃): δ = 6.27 (s, 1 H, 3-H), 6.39 (d, *J* = 15.2 Hz, 1 H, H-α), 6.86–6.99 (m, 2 H, H-γ, H-δ), 7.34 (d, *J* = 8.6 Hz, 2 H, 3',5'-H), 7.34–7.48 (m, 2 H, H-β, 6-H), 7.42 (d, *J* = 8.6 Hz, 2 H, 2',6'-H), 7.50 (dd, *J* = 8.5, 1.1 Hz, 1 H, 8-H), 7.68 (ddd, *J* = 8.5, 7.1, 1.7 Hz, 1 H, 7-H), 8.19 (dd, *J* = 7.9, 1.7 Hz, 1 H, 5-H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 110.5 (C-3), 117.8 (C-8), 124.1 (C-4a), 124.2 (C-α), 125.0 (C-6), 125.7 (C-5), 127.6 (C-γ), 128.2 (C-2',6'), 129.1 (C-3',5'), 133.8 (C-7), 134.6, 134.7 (C-1' and C-4'), 137.0 (C-β), 137.6 (C-δ), 156.0 (C-8a), 161.6 (C-2), 178.4 (C-4) ppm. EI-MS: *m/z* (%) = 310 (³⁷Cl, 9) [M + H]⁺, 309 (³⁷Cl, 23) [M]⁺, 308 (³⁵Cl, 28) [M + H]⁺, 307 (³⁵Cl, 100) [M]⁺, 291 (20), 197 (35), 152 (24). EI-HRMS: calcd. for C₁₉H₁₂³⁵ClO₂ [M – H]⁺ 307.0526; found 307.0567.

2-[(1*E*,3*E*)-4-(4-Methoxyphenyl)buta-1,3-dien-1-yl]-4*H*-chromen-4-one (3c**):** Yield 292 mg (80 %), yellow solid, m.p. 137–139 °C (from EtOH). ¹H NMR (300 MHz, CDCl₃): δ = 3.84 (s, 3 H, OCH₃), 6.24 (s, 1 H, 3-H), 6.32 (d, *J* = 15.3 Hz, 1 H, H-α), 6.84–6.87 (m, 1 H, H-δ), 6.90 (d, *J* = 8.8 Hz, 2 H, 3',5'-H), 6.90–6.96 (m, 1 H, H-γ), 7.38 (ddd, *J* = 8.2, 7.1, 0.9 Hz, 1 H, 6-H), 7.41–7.44 (m, 1 H, H-β), 7.43 (d, *J* = 8.8 Hz, 2 H, 2',6'-H), 7.49 (d, *J* = 8.1 Hz, 1 H, 8-H), 7.67 (ddd, *J* = 8.1, 7.1, 1.7 Hz, 1 H, 7-H), 8.18 (dd, *J* = 8.2, 1.7 Hz, 1 H, 5-H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 55.3 (OCH₃), 109.9 (C-3), 114.3 (C-3',5'), 117.7 (C-8), 122.3 (C-α), 124.1 (C-4a), 124.8 (C-6), 125.0 (C-γ), 125.5 (C-5), 128.5 (C-2',6'), 128.6 (C-1'), 133.6 (C-7), 137.8 (C-β), 138.9 (C-δ), 140.4 (C-8a), 160.3 (C-4'), 162.0 (C-2), 178.4 (C-4) ppm. EI-MS: *m/z* (%) = 304 (68) [M]⁺, 303 (100) [M – H]⁺, 287 (27), 197 (23). EI-HRMS: calcd. for C₂₀H₁₆O₃ [M]⁺ 304.1099; found 304.1098.

2-[(1*E*,3*E*)-4-(4-Methylphenyl)buta-1,3-dien-1-yl]-4*H*-chromen-4-one (3d**):** Yield 266 mg (77 %), orange solid, m.p. 144–147 °C (from EtOH). ¹H NMR (300 MHz, CDCl₃): δ = 2.37 (s, 3 H, CH₃), 6.25 (s, 1 H, 3-H), 6.35 (d, *J* = 15.2 Hz, 1 H, H-α), 6.88–6.99 (m, 2 H, H-γ, H-δ), 7.19 (d, *J* = 8.0 Hz, 2 H, 3',5'-H), 7.36–7.46 (m, 2 H, H-β, 6-H), 7.39 (d, *J* = 8.0 Hz, 2 H, 2',6'-H), 7.49 (dd, *J* = 8.5, 1.0 Hz, 1 H, 8-H), 7.67 (ddd, *J* = 8.5, 7.1, 1.6 Hz, 1 H, 7-H), 8.19 (dd, *J* = 8.0, 1.6 Hz, 1 H, 5-H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 21.4 (CH₃), 110.1 (C-3), 117.8 (C-8), 123.0 (C-α), 124.1 (C-4a), 124.9 (C-6), 125.7 (C-5), 126.2 (C-γ), 127.1 (C-2',6'), 129.6 (C-3',5'), 133.5 (C-1'), 133.6 (C-7), 137.7 (C-β), 139.2 (C-δ, C-4'), 156.0 (C-8a), 161.9 (C-2), 178.4 (C-4) ppm. EI-

MS: *m/z* (%) = 288 (40) [M]⁺, 287 (100) [M – H]⁺, 271 (22), 197 (33). EI-HRMS: calcd. for C₂₀H₁₆O₂ [M]⁺ 288.1150; found 288.1149.

2-[(1*E*,3*E*)-4-(4-Nitrophenyl)buta-1,3-dien-1-yl]-4*H*-chromen-4-one (3e**):** Yield 260 mg (68 %), yellow solid, m.p. 198–200 °C (from EtOH). ¹H NMR (300 MHz, CDCl₃): δ = 6.32 (s, 1 H, 3-H), 6.51 (d, *J* = 15.2 Hz, 1 H, H-α), 6.95–7.15 (m, 2 H, H-γ, H-δ), 7.38–7.48 (m, 2 H, H-β, 6-H), 7.51 (dd, *J* = 8.7, 1.0 Hz, 1 H, 8-H), 7.62 (d, *J* = 8.8 Hz, 2 H, 2',6'-H), 7.70 (ddd, *J* = 8.7, 7.1, 1.7 Hz, 1 H, 7-H), 8.20 (dd, *J* = 7.9, 1.7 Hz, 1 H, 5-H), 8.24 (d, *J* = 8.8 Hz, 2 H, 3',5'-H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 111.3 (C-3), 117.8 (C-8), 124.1 (C-4a), 124.3 (C-3',5'), 125.2 (C-6), 125.8 (C-5), 126.5 (C-α), 127.4 (C-2',6'), 131.2 (C-γ), 133.9 (C-7), 135.89, 135.94 (C-β and C-δ), 142.5 (C-1'), 147.4 (C-4'), 156.0 (C-8a), 161.0 (C-2), 178.5 (C-4) ppm. EI-MS: *m/z* (%) = 319 (57) [M + H]⁺, 318 (100) [M]⁺, 289 (50), 288 (35), 272 (33), 197 (73), 152 (27). EI-HRMS: calcd. for C₁₉H₁₂NO₄ [M – H]⁺ 318.0766; found 318.0765.

4-(4-Methoxyphenyl)-2-methyl-7-(4-oxo-4*H*-chromen-2-yl)-3a,4,7,7a-tetrahydro-1*H*-isoindole-1,3(2*H*)-dione (4c**):** This compound was isolated from the reaction of **3c** (37 mg, 0.121 mmol) with NMM (134 mg, 1.21 mmol) in dry DMF (10 mL) at 130 °C for 10 min in a multimode MV apparatus, and the residue was purified by preparative TLC with ethyl acetate/hexane (1:1) as the eluent. (4 mg, 8 %). ¹H NMR (300 MHz, CDCl₃): δ = 2.57 (s, 3 H, NCH₃), 3.40–3.49 (m, 2 H, 3a-H, 7a-H), 3.78 (s, 3 H, OCH₃), 3.95–3.99 (m, 1 H, 4-H), 4.25–4.27 (m, 1 H, 7-H), 6.14 (ddd, *J* = 9.9, 4.4, 1.9 Hz, 1 H, 6-H), 6.33 (ddd, *J* = 9.9, 5.0, 2.0 Hz, 1 H, 5-H), 6.40 (s, 1 H, 3'-H), 6.83 (d, *J* = 8.7 Hz, 2 H, 3'',5''-H), 7.00 (d, *J* = 8.7 Hz, 2 H, 2'',6''-H), 7.43 (ddd, *J* = 8.0, 7.1, 1.1 Hz, 1 H, 6'-H), 7.48 (dd, *J* = 8.3, 1.1 Hz, 1 H, 8'-H), 7.70 (ddd, *J* = 8.3, 7.1, 1.7 Hz, 1 H, 7'-H), 8.21 (dd, *J* = 8.0, 1.7 Hz, 1 H, 5'-H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 24.4 (NCH₃), 37.3 (C-7), 39.0 (C-4), 42.3 (C-7a), 44.1 (C-3a), 55.2 (OCH₃), 109.8 (C-3'), 113.8 (C-3'',5''), 117.9 (C-6'), 123.7 (C-4'a), 125.0 (C-6), 125.4 (C-6'), 125.9 (C-5'), 129.2 (C-1''), 129.9 (C-2'',6''), 132.6 (C-5), 133.9 (C-7'), 156.7 (C-8'a), 159.0 (C-4''), 167.9 (C-2'), 176.5, 177.4 (C-1 and C-3), 178.2 (C-4') ppm.

General Procedure for the Synthesis of 2-Methyl-7-(4-oxo-4*H*-chromen-2-yl)-4-aryl-3a,4,5,7a-tetrahydro-1*H*-isoindole-1,3(2*H*)-diones **5a–5e:** NMM (40.3 mg, 0.363 mmol), Sc(OTf)₃ (59.5 mg, 0.121 mmol), and the appropriate chromone **3a–3e** (0.121 mmol) were mixed in a closed vessel. The resulting mixture was heated at 165 °C under MV irradiation (monomode apparatus) for 10 min. The residue was dissolved in dichloromethane and purified by preparative TLC with ethyl acetate/hexane (1:1) as the eluent.

2-Methyl-7-(4-oxo-4*H*-chromen-2-yl)-4-phenyl-3a,4,5,7a-tetrahydro-1*H*-isoindole-1,3(2*H*)-dione (5a**):** Yield 36 mg (77 %), white solid, m.p. 220–223 °C. ¹H NMR (300 MHz, CDCl₃): δ = 2.59 (s, 3 H, NCH₃), 2.76–2.82 (m, 2 H, 5-H), 3.49 (q, *J* = 5.8 Hz, 1 H, 4-H), 3.60 (dd, *J* = 7.9, 5.8 Hz, 1 H, 3a-H), 4.15 (dd, *J* = 7.9, 1.5 Hz, 1 H, 7a-H), 6.65 (s, 1 H, 3'-H), 7.24–7.33 (m, 5 H, 2'',3'',4'',5'',6''-H, 6-H), 7.41 (ddd, *J* = 8.0, 7.1, 0.8 Hz, 1 H, 6'-H), 7.48 (dd, *J* = 8.5, 0.8 Hz, 1 H, 8'-H), 7.68 (ddd, *J* = 8.5, 7.1, 1.6 Hz, 1 H, 7'-H), 8.21 (dd, *J* = 8.0, 1.6 Hz, 1 H, 5'-H) ppm. ¹³C NMR (125 MHz, CDCl₃): δ = 24.4 (NCH₃), 28.5 (C-5), 38.2 (C-4), 40.6 (C-7a), 45.2 (C-3a), 109.0 (C-3'), 117.9 (C-8'), 124.0 (C-4'a), 125.2 (C-6), 125.7 (C-6'), 126.8 (C-5'), 127.5 (C-7), 128.0 (C-2'',6''), 128.5 (C-3'', 5''), 133.8 (C-7'), 135.9 (C-4''), 139.4 (C-1''), 156.0 (C-8'a), 161.9 (C-2'), 174.0 (C-1), 176.3 (C-3), 178.5 (C-4') ppm. EI-MS: *m/z* (%) = 386 (24) [M + H]⁺, 385 (100) [M]⁺, 274 (21), 273 (34). EI-HRMS: calcd. for C₂₄H₁₉NO₄ [M]⁺ 385.1314; found 385.1319.

4-(4-Chlorophenyl)-2-methyl-7-(4-oxo-4*H*-chromen-2-yl)-3a,4,5,7a-tetrahydro-1*H*-isoindole-1,3(2*H*)-dione (5b**):** Yield

28 mg (55 %), white solid, m.p. 209–211 °C. ¹H NMR (300 MHz, CDCl₃): δ = 2.68 (s, 3 H, NCH₃), 2.68–2.79 (m, 2 H, 5-H), 3.42 (dt, *J* = 7.8, 5.4 Hz, 1 H, 4-H), 3.59 (dd, *J* = 8.1, 5.4 Hz, 1 H, 3a-H), 4.19 (dd, *J* = 8.1, 1.7 Hz, 1 H, 7a-H), 6.65 (s, 1 H, 3'-H), 7.21 (d, *J* = 8.6 Hz, 2 H, 3'',5''-H), 7.20–7.24 (m, 1 H, 6-H), 7.29 (d, *J* = 8.6 Hz, 2 H, 2'',6''-H), 7.41 (ddd, *J* = 8.0, 7.1, 1.0 Hz, 1 H, 6'-H), 7.47 (dd, *J* = 8.5, 1.0 Hz, 1 H, 8'-H), 7.69 (ddd, *J* = 8.5, 7.1, 1.7 Hz, 1 H, 7'-H), 8.22 (dd, *J* = 8.0, 1.7 Hz, 1 H, 5'-H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 24.5 (NCH₃), 28.1 (C-5), 37.8 (C-4), 40.9 (C-7a), 45.0 (C-3a), 109.2 (C-3'), 117.8 (C-8'), 124.0 (C-4'a), 125.2 (C-6'), 125.8 (C-5'), 127.0 (C-7), 128.6 (C-2'',6''), 129.3 (C-3'',5''), 133.3 (C-1''), 133.9 (C-7'), 135.5 (C-6), 138.0 (C-4''), 156.0 (C-8'a), 161.6 (C-2'), 173.9 (C-3), 176.0 (C-1), 178.4 (C-4') ppm. EI-MS: *m/z* (%) = 421 (³⁷Cl, 23) [M]⁺, 419 (³⁵Cl, 100) [M]⁺. EI-HRMS *m/z* calcd. for C₂₄H₁₈³⁵ClNO₄ [M]⁺ 419.0924; found 419.0938.

4-(4-Methoxyphenyl)-2-methyl-7-(4-oxo-4H-chromen-2-yl)-3a,4,5,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (5c): Yield 34 mg (67 %), white solid, m.p. 222–224 °C. ¹H NMR (300 MHz, CDCl₃): δ = 2.60 (s, 3 H, NCH₃), 2.73–2.80 (m, 2 H, 5-H), 3.46 (q, *J* = 5.7 Hz, 1 H, 4-H), 3.55 (dd, *J* = 7.8, 5.7 Hz, 1 H, 3a-H), 3.77 (s, 3 H, OCH₃), 4.12 (dd, *J* = 7.8, 1.4 Hz, 1 H, 7a-H), 6.63 (s, 1 H, 3'-H), 6.82 (d, *J* = 8.7 Hz, 2 H, 3'',5''-H), 7.17 (d, *J* = 8.7 Hz, 2 H, 2'',6''-H), 7.24 (td, *J* = 4.8, 1.4 Hz, 1 H, 6-H), 7.40 (ddd, *J* = 7.7, 7.3, 0.8 Hz, 1 H, 6'-H), 7.47 (dd, *J* = 8.3, 0.8 Hz, 1 H, 8'-H), 7.68 (ddd, *J* = 8.3, 7.3, 1.6 Hz, 1 H, 7'-H), 8.21 (dd, *J* = 7.7, 1.6 Hz, 1 H, 5'-H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 24.4 (NCH₃), 29.0 (C-5), 37.5 (C-4), 40.4 (C-7a), 45.2 (C-3a), 55.2 (OCH₃), 109.0 (C-3'), 113.8 (C-3'',5''), 117.9 (C-8'), 124.0 (C-4'a), 125.1 (C-6'), 125.7 (C-5'), 126.7 (C-7), 129.1 (C-2'',6''), 131.2 (C-1''), 133.8 (C-7'), 135.9 (C-6), 156.0 (C-8'a), 158.8 (C-4''), 162.0 (C-2'), 174.1 (C-1), 176.5 (C-3), 178.5 (C-4') ppm. EI-MS: *m/z* (%) = 415 (5) [M]⁺, 385 (26), 381 (100), 353 (27), 352 (22). EI-HRMS: calcd. for C₂₅H₂₁NO₅ [M]⁺ 415.1420; found 415.1427.

2-Methyl-7-(4-oxo-4H-chromen-2-yl)-4-(4-methylphenyl)-3a,4,5,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (5d): Yield 34 mg (71 %), white solid, m.p. 223–225 °C. ¹H NMR (300 MHz, CDCl₃): δ = 2.31 (s, 3 H, CH₃), 2.61 (s, 3 H, NCH₃), 2.73–2.80 (m, 2 H, 5-H), 3.45 (q, *J* = 5.7 Hz, 1 H, 4-H), 3.57 (dd, *J* = 7.9, 5.7 Hz, 1 H, 3a-H), 4.14 (dd, *J* = 7.9, 1.4 Hz, 1 H, 7a-H), 6.65 (s, 1 H, 3'-H), 7.10, 7.15 (*J* = 8.5 Hz, 4 H, 3'',5''-H; 2'',6''-H, AA'BB'), 7.23–7.26 (m, 1 H, 6-H), 7.41 (ddd, *J* = 7.7, 7.3, 1.0 Hz, 1 H, 6'-H), 7.47 (dd, *J* = 8.2, 1.0 Hz, 1 H, 8'-H), 7.68 (ddd, *J* = 8.2, 7.3, 1.6 Hz, 1 H, 7'-H), 8.21 (dd, *J* = 7.7, 1.6 Hz, 1 H, 5'-H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 21.0 (CH₃), 24.4 (NCH₃), 28.5 (C-5), 37.9 (C-4), 40.6 (C-7a), 45.2 (C-3a), 109.0 (C-3'), 117.9 (C-8'), 124.0 (C-4'a), 125.1 (C-6'), 125.7 (C-5'), 126.7 (C-7), 127.8 (C-2'',6''), 129.1 (C-3'',5''), 133.8 (C-7'), 136.0 (C-6), 136.3 (C-1''), 137.1 (C-4''), 156.0 (C-8'a), 162.0 (C-2'), 174.1 (C-1), 176.3 (C-3), 178.5 (C-4') ppm. EI-MS: *m/z* (%) = 400 (23) [M + H]⁺, 399 (100) [M]⁺, 395 (26), 287 (32). EI-HRMS: calcd. for C₂₅H₂₁NO₄ [M]⁺ 399.1471; found 399.1476.

2-Methyl-4-(4-nitrophenyl)-7-(4-oxo-4H-chromen-2-yl)-3a,4,5,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (5e): Yield 27 mg (52 %), white solid, m.p. 162–165 °C. ¹H NMR (300 MHz, CDCl₃): δ = 2.78 (s, 3 H, NCH₃), 2.73–2.82 (m, 2 H, 5-H), 3.46 (dt, *J* = 9.8, 5.1 Hz, 1 H, 4-H), 3.71 (ddd, *J* = 8.1, 5.1, 1.3 Hz, 1 H, 3a-H), 4.31 (d, *J* = 8.1 Hz, 1 H, 7a-H), 6.70 (s, 1 H, 3'-H), 7.23 (ddd, *J* = 6.3, 3.5, 1.1 Hz, 1 H, 6-H), 7.42 (ddd, *J* = 8.1, 7.1, 1.1 Hz, 1 H, 6'-H), 7.44–7.49 (m, 1 H, 8'-H), 7.50 (d, *J* = 8.6 Hz, 2 H, 2'',6''-H), 7.70 (ddd, *J* = 8.7, 7.1, 1.7 Hz, 1 H, 7'-H), 8.20–8.23 (m, 1 H, 5'-H), 8.22 (d, *J* = 8.6 Hz, 2 H, 3'',5''-H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 24.8 (NCH₃), 26.9 (C-5), 38.5 (C-4), 41.6 (C-7a), 45.0 (C-3a), 109.4 (C-3'), 117.8 (C-8'), 123.6 (C-3'',5''), 123.9 (C-4'a), 125.3 (C-6'), 125.8 (C-5'), 127.5 (C-7), 128.8 (C-2'',6''), 134.0 (C-7'), 135.0 (C-6), 147.1 (C-4''), 147.4 (C-1''),

155.9 (C-8'a), 161.1 (C-2'), 173.6 (C-1), 175.5 (C-3), 178.4 (C-4') ppm. EI-MS: *m/z* (%) = 430 (62) [M]⁺, 400 (100), 396 (50), 383 (30), 368 (34). EI-HRMS: calcd. for C₂₄H₁₈N₂O₆ [M]⁺ 430.1165; found 430.1161.

(E)-4-(4-Methoxystyryl)-2-methyl-3a,4,5,11b-tetrahydrochromeno[3,2-e]isoindole-1,3,11(2H)-trione (6c): This compound was isolated from the reaction of **3c** (37 mg, 0.121 mmol) with NMM (67 mg, 0.605 mmol) in dry DMF (10 μL) at 160 °C for 10 min in a multimode MV apparatus, and the residue was purified by preparative TLC with ethyl acetate/hexane (1:1) as the eluent. Yield 3 mg (6 %). ¹H NMR (500 MHz, CDCl₃): δ = 2.73 (dd, *J* = 17.3, 7.4 Hz, 1 H, 5-H), 2.87 (s, 3 H, NCH₃), 2.95 (dd, *J* = 17.3, 4.2 Hz, 1 H, 5-H), 3.11–3.16 (m, 1 H, 4-H), 3.37 (dd, *J* = 8.2, 5.3 Hz, 1 H, 3-Ha), 3.79 (s, 3 H, OCH₃), 4.55 (d, *J* = 8.2 Hz, 1 H, 11b-H), 6.19 (dd, *J* = 15.7, 9.3 Hz, 1 H, α-H), 6.49 (d, 1 H, H-β, *J* = 15.7 Hz), 6.82 (d, 2 H, H-3',5', *J* = 8.6 Hz), 7.25 (d, 2 H, H-2',6', *J* = 8.6 Hz), 7.41–7.44 (m, 2 H, H-7, H-9), 7.67 (ddd, 1 H, H-8, *J* = 8.2, 7.3, 1.4 Hz), 8.29 (dd, 1 H, H-10, *J* = 7.9, 1.4 Hz) ppm. ¹³C NMR (125 MHz, CDCl₃): δ = 24.8 (NCH₃), 32.5 (C-5), 38.1 (C-11b), 39.0 (C-4), 44.5 (C-3a), 55.3 (OCH₃), 112.8 (C-11a), 114.1 (C-3',5'), 117.7 (C-7), 123.6 (C-α), 123.9 (C-10a), 125.3 (C-9), 126.4 (C-10), 127.7 (C-2',6'), 129.0 (C-1'), 132.3 (C-β), 133.8 (C-8), 155.7 (C-6a), 159.5 (C-4'), 163.6 (C-5a), 175.1 (C-3), 176.0 (C-11), 176.5 (C-1) ppm.

Bisadduct **7c** was isolated as a mixture of diastereomers from the reaction of **3c** (37 mg, 0.121 mmol) with NMM (202 mg, 1.815 mmol) in dry DMF (10 μL) at 160 °C in a multimode MV apparatus, and the residue was purified by preparative TLC with ethyl acetate/hexane (4:1) as the eluent. Further purification of the mixture of diastereomers by preparative TLC with dichloromethane/ethyl acetate (10:2) as the eluent afforded diastereomer I. Diastereomer II was characterized by ¹H and ¹³C NMR spectroscopy with a mixture with diastereomer I (enriched in diastereomer II).

rel-(3aR,4R,5aR,5bR,8aR,14bS,14cS)-4-(4-Methoxyphenyl)-2,7-dimethyl-3a,4,5,5a,5b,8a,14b,14c-octahydro-1H-chromeno[3,2-e]isoindolo[4,5-g]isoindole-1,3,6,8,9(2H,7H)-pentaone (7c, Diastereomer I): White solid, m.p. 230–232 °C. ¹H NMR (300 MHz, CDCl₃): δ = 1.98–2.11 (m, 1 H, 5-H), 2.25–2.36 (m, 1 H, 5a-H), 2.79–2.84 (m, 1 H, 5-H), 2.93, 2.94 (2s, 3 H, 2- and 7-NCH₃), 3.24 (ddd, *J* = 12.5, 4.0, 1.2 Hz, 1 H, 14b-H), 3.36 (dd, *J* = 8.7, 4.9 Hz, 1 H, 5b-H), 3.49 (dd, *J* = 9.3, 6.2 Hz, 1 H, 3a-H), 3.61–3.69 (m, 1 H, 4-H), 3.82 (s, 3 H, OCH₃), 4.14 (dd, *J* = 9.3, 4.0 Hz, 1 H, 14c-H), 4.72 (dd, *J* = 8.7, 1.3 Hz, 1 H, 8a-H), 6.92 (d, *J* = 8.6 Hz, 2 H, 3',5'-H), 7.16 (d, *J* = 8.6 Hz, 2 H, 2',6'-H), 7.39 (d, *J* = 8.3 Hz, 1 H, 13-H), 7.39–7.44 (m, 1 H, 11-H), 7.66 (ddd, *J* = 8.3, 7.2, 1.7 Hz, 1 H), 8.29 (dd, *J* = 8.0, 1.7 Hz, 1 H, 10-H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 24.8, 25.1 (2- and 7-NCH₃), 25.5 (C-5), 31.6 (C-5a), 33.7 (C-14b), 37.0 (C-4), 39.3 (C-8a), 40.3 (C-14c), 43.3 (C-5b), 45.7 (C-3a), 55.2 (OCH₃), 113.7 (C-8b and C-3',5'), 117.5 (C-11), 123.4 (C-9a), 125.4 (C-13), 126.4 (C-10), 128.7 (C-2',6'), 131.4 (C-1), 133.9 (C-12), 155.2 (C-13a), 158.6 (C-4'), 164.0 (C-14a), 174.7, 177.0 (C-6 and C-8), 175.9, 176.1 (C-1, C-3, and C-9) ppm. EI-MS: *m/z* (%) = 527 (26) [M + H]⁺, 526 (100) [M]⁺, 414 (39). EI-HRMS: calcd. for C₃₀H₂₆N₂O₇ [M]⁺ 526.1740; found 526.1754.

rel-(3aR,4R,5aS,5bS,8aS,14bS,14cS)-4-(4-Methoxyphenyl)-2,7-dimethyl-3a,4,5,5a,5b,8a,14b,14c-octahydro-1H-chromeno[3,2-e]isoindolo[4,5-g]isoindole-1,3,6,8,9(2H,7H)-pentaone (7c, Diastereomer II): ¹H NMR (500 MHz, CDCl₃): δ = 2.17–2.20 (m, 1 H, 5-H), 2.89–2.94 (m, 1 H, 5a-H), 2.89, 2.93 (2s, 3 H, 2- and 7-NCH₃), 3.30 (t, *J* = 8.3 Hz, 1 H, 5b-H), 3.41–3.52 (m, 3 H, 5-H, 4-H, 14b-H), 3.55 (dd, *J* = 7.8, 5.9 Hz, 1 H, 3a-H), 3.74–3.79 (m, 1 H, 14c-H), 3.83 (s, 3 H, OCH₃), 4.64 (dd, *J* = 8.9, 1.2 Hz, 1 H, 8a-H), 6.94 (d, *J* = 8.8 Hz, 2 H, 3',5'-H), 7.21 (d, *J* = 8.8 Hz, 2 H, 2',6'-H), 7.35 (d, *J* = 7.9 Hz, 1 H, 13-H), 7.39–7.44 (m, 1 H, 11-H), 7.62–7.70 (m, 1 H, 12-H), 8.28 (dd, *J* = 8.0, 1.3 Hz, 1 H, 10-H) ppm. ¹³C NMR (125 MHz, CDCl₃): δ = 23.8

(C-5), 25.1, 25.3 (2- and 7-NCH₃), 31.7 (C-5a), 35.5 (C-3a), 38.3 (C-8a), 38.8 (C-4), 39.3 (C-5b), 40.7 (C-14c), 45.6 (C-14b), 55.2 (OCH₃), 113.7 (C-3',5'), 114.8 (C-8b), 117.2 (C-11), 123.5 (C-9a), 125.2 (C-13), 126.6 (C-10), 128.8 (C-2',6'), 131.9 (C-1'), 133.9 (C-12), 155.4 (C-13a), 158.6 (C-4'), 161.6 (C-14a), 174.0, 177.6 (C-6 and C-8), 175.8, 175.9, 176.2 (C-1, C-3, and C-9) ppm.

4-(4-Methoxyphenyl)-7-(4-oxo-4H-chromen-2-yl)-2-phenyl-3a,4,5,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (8): *N*-Phenylmaleimide (62.8 mg, 0.363 mmol), Sc(OTf)₃ (59.5 mg, 0.121 mmol), and **3c** (0.121 mmol) were mixed in a closed vessel. The resulting mixture was heated at 165 °C under MV irradiation (monomode apparatus) for 10 min. The residue was dissolved in dichloromethane and purified by preparative TLC with ethyl acetate/hexane (1:1) as the eluent. Yield 38 mg (66 %), white solid, m.p. 212–214 °C. ¹H NMR (300 MHz, CDCl₃): δ = 2.78–2.93 (m, 2 H, 5-H), 3.54–3.74 (m, 2 H, 3a-H, 4-H), 3.75 (s, 3 H, OCH₃), 4.28 (dd, *J* = 7.1, 1.7 Hz, 1 H, 7a-H), 6.62–6.65 (m, 1 H, 6-H), 6.64 (s, 1 H, 3'-H), 6.81 (d, *J* = 8.7 Hz, 2 H, 3'',5''-H), 7.22 (d, *J* = 8.7 Hz, 2 H, 3'',5''-H), 7.24–7.30 (m, 5 H, 2''',3''',4''',5''',6'''-H), 7.39 (ddd, *J* = 7.9, 7.1, 1.0 Hz, 1 H, 6'-H), 7.47 (dd, *J* = 8.6, 1.0 Hz, 1 H, 8'-H), 7.67 (ddd, *J* = 8.6, 7.1, 1.7 Hz, 1 H, 7'-H), 8.20 (dd, *J* = 7.9, 1.7 Hz, 1 H, 5'-H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 30.0 (C-5), 37.2 (C-4), 39.9 (C-7a), 44.8 (C-3a), 55.3 (OCH₃), 108.9 (C-3'), 114.2 (C-3'',5''), 117.9 (C-8'), 124.0 (C-4'a), 125.1 (C-6'), 125.7 (C-5'), 126.2 (C-2''',6'''), 126.5 (C-6), 128.5 (C-7), 128.8 (C-3''',5'''), 129.5 (C-2'',6''), 131.0 (C-1'''), 131.3 (C-1''), 133.8 (C-7'), 135.8 (C-4'''), 156.0 (C-8'a), 159.2 (C-4''), 162.3 (C-2'), 173.0 (C-1), 175.6 (C-3), 178.4 (C-4') ppm. EI-MS: *m/z* (%) = 478 (23) [M + H]⁺, 477 (81) [M]⁺, 474 (100), 473 (29), 445 (36), 444 (45), 305 (23). EI-HRMS: calcd. for C₃₀H₂₃NO₅ [M]⁺ 477.1576; found 477.1590.

Dialkyl 4'-Methoxy-4-(4-oxo-4H-chromen-2-yl)-[1,1'-biphenyl]-2,3-dicarboxylates 9a and 9b: Dimethyl acetylenedicarboxylate (45 μL, 0.363 mmol) or diethyl acetylenedicarboxylate (58 μL, 0.363 mmol) and chromone **3c** (37 mg, 0.121 mmol) were mixed in a closed vessel. The resulting mixture was heated at 165 °C under MV irradiation (monomode apparatus) for 15 min. The residue was dissolved in dichloromethane and purified by preparative TLC with ethyl acetate/hexane (1:1) as the eluent.

Dimethyl 4'-Methoxy-4-(4-oxo-4H-chromen-2-yl)-[1,1'-biphenyl]-2,3-dicarboxylate (9a): Yield 16 mg (30 %), yellow solid, m.p. 226–227 °C. ¹H NMR (300 MHz, CDCl₃): δ = 3.69, 3.76 (2 × s, 2 × 3 H, 2,3-CO₂CH₃), 3.86 (s, 3 H, 4'-OCH₃), 6.64 (s, 1 H, 3'-H), 6.97 (d, *J* = 8.7 Hz, 2 H, 3'',5''-H), 7.31 (d, *J* = 8.7 Hz, 2 H, 2'',6''-H), 7.42 (d, *J* = 8.1 Hz, 1 H, 8'-H), 7.45 (td, *J* = 7.7, 1.0 Hz, 1 H, 6'-H), 7.60 (d, *J* = 8.1 Hz, 1 H, 6-H), 7.67–7.73 (m, 1 H, 7'-H), 7.74 (d, *J* = 8.1 Hz, 1 H, 5-H), 8.25 (dd, *J* = 8.1, 1.5 Hz, 1 H, 5'-H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 52.7, 53.1 (2,3-CO₂CH₃), 55.3 (4'-OCH₃), 110.9 (C-3'), 114.1 (C-3'',5''), 117.7 (C-8'), 123.8 (C-4'a), 125.6 (C-6'), 125.9 (C-5'), 129.4 (C-2'',6''), 130.3 (C-5), 130.4 (C-4), 131.0 (C-1''), 131.4 (C-3), 132.4 (C-6), 133.3 (C-2), 134.1 (C-7'), 143.2 (C-1), 156.3 (C-8'a), 159.8 (C-4''), 163.6 (C-2'), 167.6, 168.2 (2,3-CO₂CH₃), 178.0 (C-4') ppm. EI-MS: *m/z* (%) = 445 (20) [M + H]⁺, 444 (100) [M]⁺, 413 (36). EI-HRMS: calcd. for C₂₆H₂₀O₇ [M]⁺ 444.1209; found 444.1214.

Diethyl 4'-Methoxy-4-(4-oxo-4H-chromen-2-yl)-[1,1'-biphenyl]-2,3-dicarboxylate (9b): Yield 20 mg (35 %), yellow solid, m.p. 170–172 °C. ¹H NMR (300 MHz, CDCl₃): δ = 1.078, 1.083 (2 × 3t, *J* = 7.2 Hz, 2 × 3 H, 2- and 3-CO₂CH₂CH₃), 3.86 (s, 3 H, OCH₃), 4.14 (q, *J* = 7.2 Hz, 2 H, 2-CO₂CH₂CH₃), 4.21 (q, *J* = 7.2 Hz, 2 H, 3-CO₂CH₂CH₃), 6.63 (s, 1 H, 3'-H), 6.96 (d, *J* = 8.7 Hz, 2 H, 3'',5''-H), 7.32 (d, *J* = 8.7 Hz, 2 H, 2'',6''-H), 7.42 (d, *J* = 8.4 Hz, 1 H, 8'-H), 7.45 (ddd, *J* = 8.0, 7.2, 1.2 Hz, 1 H, 6'-H), 7.58 (d, *J* = 8.0 Hz, 1 H, 6-H), 7.70 (ddd, *J* = 8.4, 7.2, 1.7 Hz, 1 H, 7'-H), 7.72 (d, *J* = 8.0 Hz, 1 H, 5-H), 8.26 (dd, *J* = 8.0, 1.7 Hz, 1 H, 5'-H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 13.7, 13.8 (2,3-

CO₂CH₂CH₃), 55.4 (OCH₃), 61.8 (2-CO₂CH₂CH₃), 62.3 (3-CO₂CH₂CH₃), 111.0 (C-3'), 114.0 (C-3'',5''), 117.8 (C-8'), 123.8 (C-4'a), 125.5 (C-6'), 125.9 (C-5'), 129.5 (C-2'',6''), 130.2 (C-5), 130.5 (C-4), 131.2 (C-1''), 131.5 (C-3), 132.3 (C-6), 133.8 (C-2), 134.1 (C-7'), 143.2 (C-1), 156.3 (C-8'a), 159.8 (4''), 163.9 (C-2'), 167.0 (3-CO₂CH₂CH₃), 167.7 (2-CO₂CH₂CH₃), 178.0 (C-4') ppm. EI-MS: *m/z* (%) = 473 (20) [M + H]⁺, 472 (100) [M]⁺, 399 (91), 327 (21). EI-HRMS: calcd. for C₂₈H₂₄O₇ [M]⁺ 472.1522; found 472.1524.

Dialkyl 3-(4-Methoxyphenyl)-6-(4-oxo-4H-chromen-2-yl)-3,6-dihydropyridazine-1,2-dicarboxylates 10a and 10b: Diethyl azodicarboxylate toluene solution (0.14 mL, 0.363 mmol) or diisopropyl azodicarboxylate (71 μL, 0.363 mmol) and chromone **3c** (37 mg, 0.121 mmol) were mixed in a closed vessel. The resulting mixture was heated at 165 °C under MV irradiation (monomode apparatus) for 15 or 10 min, respectively. The residue was dissolved in dichloromethane and purified by preparative TLC with ethyl acetate/hexane (1:1) as the eluent.

Diethyl 3-(4-Methoxyphenyl)-6-(4-oxo-4H-chromen-2-yl)-3,6-dihydropyridazine-1,2-dicarboxylate (10a): Yield 13 mg (22 %), colorless oil. ¹H NMR (300 MHz, CDCl₃): δ = 0.71–0.77 (m, 6 H, 1,2-CO₂CH₂CH₃), 3.56–3.95 (m, 4 H, 1,2-CO₂CH₂CH₃), 3.80 (s, 3 H, OCH₃), 5.87–5.90 (m, 2 H, 3-H, 6-H), 6.21–6.24 (m, 1 H, 4-H), 6.28–6.31 (m, 1 H, 5-H), 6.45 (s, 1 H, 3'-H), 6.86 (d, *J* = 8.6 Hz, 2 H, 3'',5''-H), 7.32 (d, *J* = 8.6 Hz, 2 H, 2'',6''-H), 7.40 (ddd, *J* = 8.0, 7.1, 1.1 Hz, 1 H, 6'-H), 7.49 (d, *J* = 8.3 Hz, 1 H, 8'-H), 7.67 (ddd, *J* = 8.3, 7.1, 1.7 Hz, 1 H, 7'-H), 8.18 (dd, *J* = 8.0, 1.7 Hz, 1 H, 5'-H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 13.8, 13.9 (1,2-CO₂CH₂CH₃), 53.8 (C-6), 54.8 (C-3), 55.4 (OCH₃), 62.3, 62.5 (1,2-CO₂CH₂CH₃), 111.1 (C-3'), 113.8 (C-3'',5''), 118.2 (C-8'), 121.9 (C-4), 123.8 (C-4'a), 125.3 (C-6'), 125.7 (C-5'), 129.4 (C-1''), 129.5 (C-5), 129.8 (C-2'',6''), 133.9 (C-7'), 154.9, 155.5 (1,2-CO₂CH₂CH₃), 156.4 (C-8'a), 159.7 (C-4''), 163.8 (C-2'), 178.2 (C-4') ppm. EI-MS: *m/z* (%) = 478 (17) [M]⁺, 405 (54), 390 (33), 389 (86), 318 (75), 317 (54), 303 (100), 197 (69). EI-HRMS: calcd. for C₂₆H₂₆N₂O₇ [M]⁺ 478.1740; found 478.1745.

Diisopropyl 3-(4-Methoxyphenyl)-6-(4-oxo-4H-chromen-2-yl)-3,6-dihydropyridazine-1,2-dicarboxylate (10b): Yield 35 mg (57 %), yellow oil. ¹H NMR (300 MHz, CDCl₃): δ = 0.530, 0.97 (2 × d, *J* = 6.2 Hz, 2 × 3 H, 4''',5''''-CH₃), 0.531, 1.03 (2 × d, *J* = 6.2 Hz, 2 × 3 H, 4''',5''''-CH₃), 3.79 (s, 3 H, 4'-OCH₃), 4.60 (sept, *J* = 6.3 Hz, 1 H, 3''-H), 4.71 (sept, *J* = 6.3 Hz, 1 H, 3''''-H), 5.87–5.92 (m, 2 H, 3-H, 6-H), 6.19–6.32 (m, 2 H, 4-H, 5-H), 6.86 (d, *J* = 8.7 Hz, 2 H, 3'',5''-H), 7.33 (d, *J* = 8.7 Hz, 2 H, 2'',6''-H), 7.40 (ddd, *J* = 8.0, 7.1, 1.0 Hz, 1 H, 6'-H), 7.50 (dd, *J* = 8.6, 1.0 Hz, 1 H, 8'-H), 7.67 (ddd, *J* = 8.6, 7.1, 1.7 Hz, 1 H, 7'-H), 8.18 (dd, *J* = 8.0, 1.7 Hz, 1 H, 5'-H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 20.9, 21.2 (5''''- and 4''''-CH₃), 21.81, 21.83 (5'''- and 4'''-CH₃), 53.5 (C-6), 54.5 (C-6), 55.4 (4'-OCH₃), 69.9 (C-3'''), 70.3 (C-3'''), 111.2 (C-3'), 113.8 (C-3'',5''), 118.3 (C-8'), 121.8 (C-4 or C-5), 123.9 (C-4'a), 125.3 (C-6'), 125.6 (C-5'), 129.6, 129.7 (C-1 and C-4 or C-5), 129.8 (C-2'',6''), 133.9 (C-7'), 154.4 (C-1'''), 154.8 (C-1'''), 156.4 (C-8'a), 159.7 (C-4''), 163.9 (C-2'), 178.2 (C-4') ppm. EI-MS: *m/z* (%) = 506 (5) [M]⁺, 420 (67), 403 (28), 333 (42), 318 (71), 317 (100), 316 (21), 305 (89), 303 (63), 302 (34), 197 (39). EI-HRMS: calcd. for C₂₈H₃₀N₂O₇ [M]⁺ 506.2053; found 506.2061.

4-[1,2-Bis(ethoxycarbonyl)hydrazinyl]-3-(4-methoxyphenyl)-6-(4-oxo-4H-chromen-2-yl)-3,4-dihydropyridazine-1,2-dicarboxylate (11): Diethyl azodicarboxylate solution (0.14 mL, 0.363 mmol) and **3c** (37 mg, 0.121 mmol) were mixed in a closed vessel. The resulting mixture was heated at 130 °C under MV irradiation (monomode apparatus) for 10 min. The residue was dissolved in dichloromethane and purified by preparative TLC with ethyl acetate/hexane (1:1) as the eluent. Yield 24 mg (30 %), yellow solid, m.p. 110–112 °C. ¹H NMR (500 MHz, [D₆]DMSO, 80 °C): δ = 0.81, 1.10 (2 × t, *J* = 7.0 Hz,

2 × 3 H, 2 × CH₃), 1.14–1.17 (m, 3 H, CH₃), 1.25 (t, *J* = 7.0 Hz, 3 H, CH₃), 3.66–3.83 (m, 2 H, CH₂), 3.75 (s, 3 H, OCH₃), 4.01–4.09 (m, 4 H, CH₂), 4.13–4.20 (m, 2 H, CH₂), 5.07 (br s, 1 H, 3-H), 5.70 (br s, 1 H, 4-H), 6.49 (s, 1 H, 3'-H), 6.53 (br s, 1 H, 5-H), 6.92 (d, *J* = 8.5 Hz, 2 H, 3'',5''-H), 7.27 (d, *J* = 8.5 Hz, 2 H, 2'',6''-H), 7.50 (ddd, *J* = 8.0, 7.2, 1.0 Hz, 1 H, 6'-H), 7.61 (dd, *J* = 8.0, 1.0 Hz, 1 H, 8'-H), 7.82 (ddd, *J* = 8.6, 7.2, 1.7 Hz, 1 H, 7'-H), 8.05 (dd, *J* = 8.0, 1.7 Hz, 1 H, 5'-H), 9.07 (br s, 1 H, NH) ppm. ¹³C NMR (125 MHz, [D₆]DMSO, 80 °C): δ = 13.2 (CH₃), 13.7 (CH₃), 13.81 (CH₃), 13.83 (CH₃), 54.9 (OCH₃ and C-3), 60.7 (CH₂), 61.8 (CH₂), 62.0 (CH₂), 62.2 (CH₂ and C-4), 107.9 (C-3'), 113.7 (C-3'',5''), 117.8 (C-8'), 121.2 (C-5), 123.1 (C-4'a), 124.5 (C-5'), 125.3 (C-6'), 128.5 (C-2'',6''), 129.4 (C-1''), 134.1 (C-7'), 136.0 (C-6), 152.4 (CO₂), 153.3 (CO₂), 154.3 (CO₂), 154.4 (CO₂), 155.1 (C-8'a), 158.2 (C-2'), 159.0 (C-4''), 176.3 (C-4') ppm. EI-MS: *m/z* (%) = 652 (1) [M]⁺, 405 (96), 372 (74), 359 (50), 331 (96), 225 (77), 208 (100). EI-HRMS: calcd. for C₃₂H₃₆N₄O₁₁ [M]⁺ 652.2381; found 652.2386.

General Procedure for the Synthesis of 4-(4-Oxo-4H-chromen-2-yl)-7-arylisindoline-1,3-diones 12a–12e and 14: DDQ (65.4 mg, 0.288 mmol) was added to a solution of the appropriate adduct **5a–5e** and **8** (0.072 mmol) in 1,2,4-TCB (0.5 mL). The mixture was heated at 165 °C under MV irradiation (monomode apparatus) for 25 min. The residue was treated with a sodium hydrogen carbonate aqueous solution (20 mL), and the aqueous layer was extracted with dichloromethane (3 × 50 mL). The organic layer was dried with anhydrous sodium sulfate, and the solvent was evaporated to dryness. The residue was purified by preparative TLC with hexane followed by ethyl acetate/hexane (9:7) as the eluent.

2-Methyl-4-(4-oxo-4H-chromen-2-yl)-7-phenylisindoline-1,3-dione (12a): Yield 23 mg (85 %), white solid, m.p. 243–245 °C. ¹H NMR (300 MHz, CDCl₃): δ = 3.15 (s, 3 H, NCH₃), 6.76 (s, 1 H, 3'-H), 7.47 (ddd, *J* = 8.0, 7.0, 1.0 Hz, 1 H, 6'-H), 7.49–7.59 (m, 6 H, 2'',3'',4'',5'',6''-H; 8'-H), 7.73 (ddd, *J* = 8.5, 7.0, 1.7 Hz, 1 H, 7'-H), 7.77 (d, *J* = 8.0 Hz, 1 H, 5-H), 7.93 (d, *J* = 8.0 Hz, 1 H, 6-H), 8.29 (dd, *J* = 8.0, 1.7 Hz, 1 H, 5'-H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 24.1 (NCH₃), 112.7 (C-3'), 118.2 (C-8'), 124.0 (C-4'a), 125.5 (C-6'), 125.8 (C-5'), 128.2 (C-2'',6''), 129.0 (C-3a), 129.2 (C-4''), 129.4 (C-3'',5'' and C-7), 130.6 (C-7a), 133.9 (C-6), 134.2 (C-7'), 135.5 (C-1''), 136.2 (C-5), 143.1 (C-4), 156.6 (C-8'a), 160.9 (C-2'), 165.9, 166.9 (C-1 and C-3), 178.1 (C-4') ppm. EI-MS: *m/z* (%) = 382 [M + H]⁺ (21), 381 [M]⁺ (100), 353 (23), 325 (26). EI-HRMS: calcd. for C₂₄H₁₅NO₄ [M]⁺ 381.1001; found 381.1005.

4-(4-Chlorophenyl)-2-methyl-7-(4-oxo-4H-chromen-2-yl)isindoline-1,3-dione (12b): Yield 22 mg (75 %), white solid, m.p. 214–216 °C. ¹H NMR (300 MHz, CDCl₃): δ = 3.16 (s, 3 H, NCH₃), 6.75 (s, 1 H, 3'-H), 7.44–7.55 (m, 6 H, 6'-H, 8'-H, 2'',6''-H, 3'',5''-H), 7.73 (ddd, *J* = 8.6, 7.1, 1.7 Hz, 1 H, 7'-H), 7.74 (d, *J* = 8.0 Hz, 1 H, 5-H), 7.94 (d, *J* = 8.0 Hz, 1 H, 6-H), 8.28 (dd, *J* = 8.0, 1.7 Hz, 1 H, 5'-H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 24.2 (NCH₃), 112.8 (C-3'), 118.2 (C-8'), 124.0 (C-4'a), 125.5 (C-6'), 125.8 (C-5'), 128.5 (C-3'',5''), 129.0 (C-3a), 129.7 (C-7), 130.6 (C-7a), 130.7 (C-2'',6''), 133.9 (C-4''), 134.1 (C-7'), 134.2 (C-6), 135.6 (C-1''), 136.0 (C-5), 141.7 (C-4), 156.6 (C-8'a), 160.7 (C-2'), 165.8, 166.8 (C-1 and C-3), 178.0 (C-4') ppm. EI-MS: *m/z* (%) = 417 [M]⁺ (³⁷Cl, 24), 415 [M]⁺ (³⁵Cl, 100). EI-HRMS: calcd. for C₂₄H₁₄³⁵ClNO₄ [M]⁺ 415.0611; found 415.0624.

4-(4-Methoxyphenyl)-2-methyl-7-(4-oxo-4H-chromen-2-yl)isindoline-1,3-dione (12c): Yield 27 mg (90 %), yellow solid, m.p. 217–219 °C. ¹H NMR (300 MHz, CDCl₃): δ = 3.16 (s, 3 H, NCH₃), 3.90 (s, 3 H, OCH₃), 6.75 (s, 1 H, 3'-H), 7.04 (d, *J* = 8.8 Hz, 2 H, 3'',5''-H), 7.46 (td, *J* = 7.7, 1.0 Hz, 1 H, 6'-H), 7.50–7.52 (m, 1 H, 8'-H), 7.55 (d, *J* = 8.8 Hz, 2 H, 2'',6''-H), 7.70–7.76 (m, 1 H, 7'-H), 7.75 (d, *J* = 8.1 Hz, 1 H, 5-H), 7.90 (d, *J* = 8.1 Hz, 1 H, 6-H), 8.28 (dd, *J* = 7.7, 1.6 Hz, 1

H, 5'-H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 24.1 (NCH₃), 55.4 (OCH₃), 112.6 (C-3'), 113.7 (C-3'',5''), 118.2 (C-8'), 124.0 (C-4'a), 125.4 (C-6'), 125.8 (C-5'), 127.7 (C-1''), 128.6 (C-3a), 128.8 (C-7), 130.7 (C-7a), 130.9 (C-2'',6''), 133.9 (C-6), 134.1 (C-7'), 136.1 (C-5), 142.9 (C-4), 156.6 (C-8'a), 160.5 (C-4''), 161.0 (C-2'), 166.0, 167.1 (C-1 and C-3), 178.1 (C-4') ppm. EI-MS: *m/z* (%) = 412 [M + H]⁺ (21), 411 [M]⁺ (100). EI-HRMS: calcd. for C₂₅H₁₇NO₅ [M]⁺ 411.1107; found 411.1106.

2-Methyl-4-(4-oxo-4H-chromen-2-yl)-7-(methylphenyl)isindoline-1,3-dione (12d): Yield 23 mg (80 %), white solid, m.p. 221–223 °C. ¹H NMR (300 MHz, CDCl₃): δ = 2.45 (s, 3 H, CH₃), 3.15 (s, 3 H, NCH₃), 6.75 (s, 1 H, 3'-H), 7.32 (d, *J* = 8.0 Hz, 2 H, 3'',5''-H), 7.44–7.50 (m, 1 H, 6'-H), 7.48 (d, *J* = 8.0 Hz, 2 H, 2'',6''-H), 7.52 (dd, *J* = 8.8, 1.0 Hz, 1 H, 8'-H), 7.73 (ddd, *J* = 8.8, 7.1, 1.5 Hz, 1 H, 7'-H), 7.75 (d, *J* = 8.0 Hz, 1 H, 5-H), 7.91 (d, *J* = 8.0 Hz, 1 H, 6-H), 8.28 (dd, *J* = 7.9, 1.5 Hz, 1 H, 5'-H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 21.4 (CH₃), 24.1 (NCH₃), 112.7 (C-3'), 118.2 (C-8'), 124.0 (C-4'a), 125.5 (C-6'), 125.8 (C-5'), 128.9 (C-3a), 129.0 (C-3'',5''), 129.1 (C-7), 129.3 (C-2'',6''), 130.6 (C-7a), 132.6 (C-1''), 133.9 (C-6), 134.1 (C-7'), 136.2 (C-5), 139.4 (C-4''), 143.2 (C-4), 156.6 (C-8'a), 161.0 (C-2'), 166.0, 167.0 (C-1 and C-3), 178.1 (C-4') ppm. EI-MS: *m/z* (%) = 395 [M]⁺ (100). EI-HRMS: calcd. for C₂₅H₁₇NO₄ [M]⁺ 395.1158; found 395.1157.

2-Methyl-4-(4-nitrophenyl)-7-(4-oxo-4H-chromen-2-yl)isindoline-1,3-dione (12e): Yield 21 mg (70 %), yellow solid, m.p. 266–269 °C. ¹H NMR (300 MHz, CDCl₃): δ = 3.17 (s, 3 H, NCH₃), 6.78 (s, 1 H, 3'-H), 7.48 (ddd, *J* = 8.0, 7.1, 1.0 Hz, 1 H, 6'-H), 7.52 (d, *J* = 7.0 Hz, 1 H, 8'-H), 7.72–7.78 (m, 1 H, 7'-H), 7.74 (d, *J* = 8.9 Hz, 2 H, 2'',6''-H), 7.78 (d, *J* = 8.0 Hz, 1 H, 5-H), 8.01 (d, *J* = 8.0 Hz, 1 H, 6-H), 8.29 (dd, *J* = 8.0, 1.2 Hz, 1 H, 5'-H), 8.38 (d, *J* = 8.9 Hz, 2 H, 3'',5''-H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 24.3 (NCH₃), 113.0 (C-3'), 118.2 (C-8'), 123.4 (C-3'',5''), 124.0 (C-4'a), 125.6 (C-6'), 125.9 (C-5'), 129.5 (C-3a), 130.5 (C-2'',6''), 130.67, 130.71 (C-7 and C-7a), 134.3 (C-7', C-6), 135.7 (C-5), 140.1 (C-4), 141.9 (C-1''), 148.2 (C-4''), 156.6 (C-8'a), 160.2 (C-2'), 165.5, 165.6 (C-1 and C-3), 177.9 (C-4') ppm. EI-MS: *m/z* (%) = 426 [M]⁺ (17), 396 (100). EI-HRMS: calcd. for C₂₄H₁₄N₂O₆ [M]⁺ 426.0852; found 426.0855.

4-(4-Methoxyphenyl)-7-(4-oxo-4H-chromen-2-yl)-2-phenylisindoline-1,3-dione (14): Yield 29 mg (86 %), white solid, m.p. 271–272 °C. ¹H NMR (300 MHz, CDCl₃): δ = 3.88 (s, 3 H, OCH₃), 6.75 (s, 1 H, 3'-H), 7.03 (d, *J* = 8.8 Hz, 2 H, 3'',5''-H), 7.35–7.38 (m, 1 H, 4''-H), 7.39–7.48 (m, 5 H, 6'-H, 2'',6''-H, 3'',5''-H), 7.50 (dd, *J* = 8.4, 0.6 Hz, 1 H, 8'-H), 7.59 (d, *J* = 8.8 Hz, 2 H, 2'',6''-H), 7.70 (ddd, *J* = 8.4, 7.2, 1.4 Hz, 1 H, 7'-H), 7.84 (d, *J* = 8.1 Hz, 1 H, 5-H), 7.96 (d, *J* = 8.1 Hz, 1 H, 6-H), 8.27 (dd, *J* = 8.0, 1.4 Hz, 1 H, 5'-H) ppm. ¹³C NMR (75 MHz, CDCl₃): δ = 55.4 (OCH₃), 112.7 (C-3'), 113.7 (C-3'',5''), 118.3 (C-8'), 124.0 (C-4'a), 125.5 (C-6'), 125.8 (C-5'), 126.7 (C-2'',6''), 127.6 (C-1''), 128.0 (C-3a), 128.3 (C-4''), 129.0 (C-3'',5''), 129.3 (C-7), 130.3 (C-7a), 131.0 (C-2'',6''), 131.3 (C-1''), 134.1 (C-7'), 134.5 (C-6), 136.6 (C-5), 143.5 (C-4), 156.7 (C-8'a), 160.6 (C-4''), 161.2 (C-2'), 164.9, 166.1 (C-1 and C-3), 178.1 (C-4) ppm. EI-MS: *m/z* (%) = 477 (100), 473 [M]⁺ (95), 444 (54), 222 (77). EI-HRMS: calcd. for C₃₀H₁₉NO₅ [M]⁺ 473.1263; found 473.1277.

4-(4-Methoxyphenyl)-2-methyl-7-(4-oxo-4H-chromen-2-yl)-3a,7a-dihydro-1H-isindole-1,3(2H)-dione (13c): This compound was obtained as a byproduct in the synthesis of **12c** by the same procedure described above but under classical heating conditions with toluene and 1,4-dioxane at 100 °C and 1,2,4-TCB at 190 °C. After a few hours, the oxidation reaction afforded a mixture of the oxidized product **12c** and the semioxidized product **13c**. Yield 15–60 mg, m.p. 214–216 °C. ¹H NMR (300 MHz, CDCl₃): δ = 2.98 (s, 3 H, NCH₃), 3.85 (s, 3 H, OCH₃), 4.44 (d, *J* = 11.6 Hz, 1 H, 7a-H), 4.61 (d, *J* = 11.6 Hz, 1 H, 3a-H), 6.45 (dd, *J* = 6.9, 1.8 Hz, 1 H, 5-H), 6.65 (s, 1 H, 3'-H), 6.95 (d, *J* = 8.8 Hz, 2 H, 3'',5''-H), 7.14 (d, *J* = 6.9 Hz, 1 H,

6-H), 7.40 (ddd, $J = 8.0, 7.1, 1.0$ Hz, 1 H, 6'-H), 7.47 (dd, $J = 8.5, 1.0$ Hz, 1 H, 8'-H), 7.54 (d, $J = 8.8$ Hz, 2 H, 2'',6''-H), 7.67 (ddd, $J = 8.5, 7.1, 1.7$ Hz, 1 H, 7'-H), 8.20 (dd, $J = 8.0, 1.7$ Hz, 1 H, 5'-H) ppm. ^{13}C NMR (75 MHz, CDCl_3): $\delta = 25.8$ (NCH_3), 41.1 (C-7a), 43.7 (C-3a), 55.4 (OCH_3), 108.8 (C-3'), 113.9 (C-3'',5''), 117.8 (C-8'), 119.9 (C-5), 121.5 (C-7), 124.1 (C-4'a), 125.1 (C-6'), 125.7 (C-5'), 127.9 (C-6), 128.1 (C-2'',6''), 129.7 (C-1''), 133.8 (C-7'), 136.4 (C-4), 156.0 (C-8'a), 160.5 (C-4''), 161.8 (C-2'), 175.1, 175.3 (C-1 and C-3), 178.3 (C-4') ppm. EI-MS: m/z (%) = 414 (24) $[\text{M} + \text{H}]^+$, 413 (100) $[\text{M}]^{+}$. EI-HRMS: calcd. for $\text{C}_{25}\text{H}_{19}\text{NO}_5$ $[\text{M}]^+$ 413.1263; found 413.1261.

Diisopropyl [(1Z,3Z)-1-(4-Methoxyphenyl)-4-(4-oxo-4H-chromen-2-yl)buta-1,3-diene-1,4-diyldicarbamate (15b): DDQ (56.3 mg, 0.248 mmol) was added to a solution of cycloadduct **10b** (63 mg, 0.124 mmol) in 1,2,4-TCB (0.5 mL). The mixture was heated at 165 °C under MV irradiation (monomode apparatus) for 25 min. The residue was treated with a sodium hydrogen carbonate aqueous solution (10 mL), and the aqueous layer was extracted with dichloromethane (3×15 mL). The organic layer was dried with anhydrous sodium sulfate, and the solvent was evaporated to dryness. The residue was purified by preparative TLC with hexane followed by dichloromethane/ethyl acetate (10:1) as the eluent. Yield 8.8 mg (17%), yellow oil. ^1H NMR (500 MHz, $[\text{D}_6]\text{DMSO}$, 75 °C): $\delta = 0.82, 0.94, 1.20, 1.25$ [$4 \times \text{d}$, $J = 6.2$ Hz, 3 H, $\text{CO}_2\text{CH}(\text{CH}_3)_2$], 3.78 (s, 3 H, OCH_3), 4.60, 4.84 [$2 \times \text{sept}$, $J = 6.2$ Hz, 1 H, $\text{CO}_2\text{CH}(\text{CH}_3)_2$], 6.05 (d, $J = 5.9$ Hz, 1 H, 2-H), 6.07 (s, 1 H, 1-NH), 6.26 (d, $J = 5.9$ Hz, 1 H, 3-H), 6.47 (s, 1 H, 3'-H), 6.95 (d, $J = 8.9$ Hz, 2 H, 3'',5''-H), 7.48–7.51 (m, 2 H, 6'-H, 8'-H), 7.54 (d, $J = 8.9$ Hz, 2 H, 2'',6''-H), 7.83 (ddd, $J = 8.7, 7.1, 1.7$ Hz, 1 H, 7'-H), 7.88 (br s, 1 H, 4-NH), 8.04 (dd, $J = 7.9, 1.7$ Hz, 1 H, 8'-H) ppm. ^{13}C NMR (125 MHz, $[\text{D}_6]\text{DMSO}$, 75 °C): $\delta = 20.7, 20.9, 21.4, 21.5$ [$1,4\text{-NHCO}_2\text{CH}(\text{CH}_3)_2$], 54.9 (OCH_3), 67.75, 67.80 [$1,4\text{-NHCO}_2\text{CH}(\text{CH}_3)_2$], 79.7 (C-4), 94.3 (C-1), 108.8 (C-3'), 112.5 (C-3'',5''), 117.6 (C-8'), 122.8 (C-4'a), 124.5 (C-5'), 125.3 (C-6'), 127.3 (C-2'',6''), 127.6 (C-3), 133.1 (C-1''), 134.2 (C-7'), 136.7 (C-2), 150.5, 154.5 [$1,4\text{-NHCO}_2\text{CH}(\text{CH}_3)_2$], 155.2 (C-8'a), 158.5 (C-4''), 163.7 (C-2'), 176.6 (C-4') ppm. EI-MS: m/z (%) = 504 $[\text{M}]^{+}$ (34), 418 (68), 377 (84), 358 (93), 332 (100). EI-HRMS: calcd. for $\text{C}_{28}\text{H}_{28}\text{N}_2\text{O}_7$ $[\text{M}]^+$ 504.1897; found 504.1898.

Computational Details: All quantum chemical calculations were performed with the Gaussian 09 software package.^[24] The optimized geometries and respective electronic energies were computed at the M06-2X/6-31+G(d,p) level of theory.^[25] The structures found were confirmed to correspond to true minima by frequency calculations at the same level of theory, and no imaginary frequencies were found. For some cases, the enthalpies at $T = 298$ K, $H_{298\text{K}}$, were calculated by considering the contributions of E_{el} , zero-point energy (ZPE), and thermal enthalpy to $T = 298.15$ K; no scaling factors were used (this is a reasonable approximation for relative comparisons of molecular energetics). The energies of the HOMOs and LUMOs for the optimized geometries of various dienes and dienophiles were computed at the M06-2X/6-31+G(d,p) (within the KS-MO formalism) and MP2/6-31+G(d,p) levels (Hartree-Fock MOs). The HOMO/LUMO energy gap between the diene and dienophile was calculated as $E_{\text{LUMO}}(\text{dienophile}) - E_{\text{HOMO}}(\text{diene})$; E_{LUMO} and E_{HOMO} are the calculated energies of the respective molecular orbitals. All calculations were performed without symmetry restrictions.

Acknowledgments

Thanks are due to University of Aveiro and FCT/Ministério da Educação e Ciência (MEC) for the financial support of the QOPNA research unit (FCT UID/UI00062/2013) and CIQ-UP (Pest-C/UI00081/2013) through national funds and, where

applicable, cofinanced by the FEDER, within the PT2020 Partnership Agreement, and to the Portuguese NMR Network, as well as to the Instituto Politécnico de Bragança. H. M. T. A. and C. F. R. A. C. L. are grateful to FCT for their PhD (SFRH/BD/86277/2012) and Postdoctoral (SFRH/BPD/77972/2011) grants, respectively.

Keywords: Cycloaddition · Oxygen heterocycles · Microwave chemistry · Lewis acids

- [1] a) W. Huang, M.-Z. Liu, Y. Li, Y. Tan, G.-F. Yang, *Bioorg. Med. Chem.* **2007**, *15*, 5191–5197; b) K. Kanagalakshmi, M. Premanathan, R. Priyanka, B. Hemalatha, A. Vanangamudi, *Eur. J. Med. Chem.* **2010**, *45*, 2447–2452.
- [2] F. M. Awadallah, T. A. El-Waei, M. M. Hanna, S. E. Abbas, M. Ceruso, B. E. Oz, O. O. Guler, C. T. Supuran, *Eur. J. Med. Chem.* **2015**, *96*, 425–435.
- [3] a) M. M. Dias, N. F. Machado, M. P. Marques, *Food Funct.* **2011**, *2*, 595–602; b) A. Gomes, O. Neuwirth, M. Freitas, D. Couto, D. Ribeiro, A. G. P. R. Figueiredo, A. M. S. Silva, R. S. G. R. Seixas, D. C. G. A. Pinto, A. C. Tomé, J. A. S. Cavaleiro, E. Fernandes, J. L. F. C. Lima, *Bioorg. Med. Chem.* **2009**, *17*, 7218–7226; c) P. Yadav, B. Parshad, P. Manchanda, S. K. Sharma, *Curr. Top. Med. Chem.* **2014**, *14*, 2552–2575.
- [4] a) A. Gomes, E. Fernandes, A. M. S. Silva, D. C. G. A. Pinto, C. M. M. Santos, J. A. S. Cavaleiro, J. L. F. C. Lima, *Biochem. Pharmacol.* **2009**, *78*, 171–177; b) Shaveta, A. Singh, M. Kaur, S. Sharma, R. Bhatti, P. Singh, *Eur. J. Med. Chem.* **2014**, *77*, 185–192.
- [5] O. Prakash, R. Kumar, V. Parkash, *Eur. J. Med. Chem.* **2008**, *43*, 435–440.
- [6] M. A. Ibrahim, T. E. Ali, Y. A. Alnamer, Y. A. Gabr, *ARKIVOC (Gainesville, FL, U.S.)* **2010**, 98–135.
- [7] R. A. A. Foster, M. C. Willis, *Chem. Soc. Rev.* **2013**, *42*, 63–76.
- [8] A. Schönberg, A. Mustafa, G. Aziz, *J. Am. Chem. Soc.* **1954**, *76*, 4576–4577.
- [9] A. Mustafa, M. I. Ali, *J. Org. Chem.* **1956**, *21*, 849–851.
- [10] R. M. Letcher, T.-Y. Yue, *J. Chem. Res. Synop.* **1992**, 248.
- [11] A. S. Kelkar, R. M. Letcher, K.-K. Cheung, K.-F. Chiu, G. D. Brown, *J. Chem. Soc. Perkin Trans. 1* **2000**, 3732–3741.
- [12] H. M. T. Albuquerque, C. M. M. Santos, J. A. S. Cavaleiro, A. M. S. Silva, *Eur. J. Org. Chem.* **2015**, 4732–4743.
- [13] a) H. R. El-Seedi, M. A. El-Barbary, D. M. El-Ghorab, L. Bohlin, A. K. Borg-Karlson, U. Goransson, R. Verpoorte, *Curr. Med. Chem.* **2010**, *17*, 854–901; b) J. A. Manthey, K. Grohmann, N. Guthrie, *Curr. Med. Chem.* **2001**, *8*, 135–153.
- [14] a) Shagufta, I. Ahmad, *Eur. J. Med. Chem.* **2016**, *116*, 267–280; b) M. Dai, X. Yuan, J. Kang, Z.-J. Zhu, R.-C. Yue, H. Yuan, B.-Y. Chen, W.-D. Zhang, R.-H. Liu, Q.-Y. Sun, *Eur. J. Med. Chem.* **2013**, *69*, 159–166; c) C. Proença, H. M. T. Albuquerque, D. Ribeiro, M. Freitas, C. M. M. Santos, A. M. S. Silva, E. Fernandes, *Eur. J. Med. Chem.* **2016**, *115*, 381–392.
- [15] M. Singh, M. Kaur, O. Silakari, *Eur. J. Med. Chem.* **2014**, *84*, 206–239.
- [16] K. Nepali, S. Sharma, M. Sharma, P. M. S. Bedi, K. L. Dhar, *Eur. J. Med. Chem.* **2014**, *77*, 422–487.
- [17] P.-L. Zhao, W.-F. Ma, A.-N. Duan, M. Zou, Y.-C. Yan, W.-W. You, S.-G. Wu, *Eur. J. Med. Chem.* **2012**, *54*, 813–822.
- [18] a) N. Guziar, M. Bajda, J. Rakoczy, B. Brus, S. Gobec, B. Malawska, *Bioorg. Med. Chem.* **2015**, *23*, 1629–1637; b) N. Guziar, M. Bajda, M. Skrok, K. Kurpiewska, K. Lewiński, B. Brus, A. Pišlar, J. Kos, S. Gobec, B. Malawska, *Eur. J. Med. Chem.* **2015**, *92*, 738–749.
- [19] C. I. C. Esteves, C. M. M. Santos, C. M. Brito, A. M. S. Silva, J. A. S. Cavaleiro, *Synlett* **2011**, 1403–1406.
- [20] G. Battistuzzi, S. Cacchi, G. Fabrizi, *Org. Lett.* **2003**, *5*, 777–780.
- [21] a) M. A. Murcko, H. Castejon, K. B. Wiberg, *J. Phys. Chem.* **1996**, *100*, 16162–16168; b) W. A. Herrebout, B. J. van der Veken, A. Wang, J. R. Durig, *J. Phys. Chem.* **1995**, *99*, 578–585.
- [22] D. W. Borhani, F. D. Greene, *J. Org. Chem.* **1986**, *51*, 1563–1570.
- [23] a) D. Walker, J. D. Hiebert, *Chem. Rev.* **1967**, *67*, 153–195; b) A. E. Wendlandt, S. S. Stahl, *Angew. Chem. Int. Ed.* **2015**, *54*, 14638–14658; *Angew. Chem.* **2015**, *127*, 14848.
- [24] M. Frisch, G. Trucks, H. B. Schlegel, G. Scuseria, M. Robb, J. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G. Petersson, H. Nakatsuji, M. Cari-

cato, X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. A. Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, N. Rega, J. M. Millam, M. Klene, J. E. Knox, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski,

R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, P. Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, Ö. Farkas, J. B. Foresman, J. V. Ortiz, J. Cioslowski, D. J. Fox, *Gaussian 09*, Gaussian, Inc., Wallingford, CT, **2009**, 19, p. 227–238.

[25] Y. Zhao, D. G. Truhlar, *Theor. Chem. Acc.* **2008**, 120, 215–241.

Received: August 31, 2016

Published Online: November 25, 2016